Study,File,Variable,Variable Label,Type,N Non-missing,N Missing,Lowest Value,10% Value,20% Value,30% Value,40% Value,50% Value,60% Value,70% Value,80% Value,90% Value,Highest Value
EMD_NCT01016483_1_mek,AE,STUDYID,Study Identifier,Char,930,0,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003
EMD_NCT01016483_1_mek,AE,DOMAIN,Domain Abbreviation,Char,930,0,AE,AE,AE,AE,AE,AE,AE,AE,AE,AE,AE
EMD_NCT01016483_1_mek,AE,USUBJID,Unique Subject Identifier,Char,930,0,1,5,8,16,21,21,26,32,36,39,44
EMD_NCT01016483_1_mek,AE,AESEQ,Sequence Number,Num,930,0,1,3,5,8,11,15,21,32,55,102,187
EMD_NCT01016483_1_mek,AE,AESPID,Sponsor-Defined Identifier,Char,930,0,1,11,130,162,2,26,34,45,6,8,99
EMD_NCT01016483_1_mek,AE,AETERM,Reported Term for the Adverse Event,Char,0,930,,,,,,,,,,,
EMD_NCT01016483_1_mek,AE,AELLT,Lowest Level Term,Char,930,0,ALT increased,Asthenia,Diarrhea,Fatigue,GOT increased,Hypokalemia,Leucopenia,Neutropenia,Pleural effusion,Thrombocytopenia,White blood cell decreased
EMD_NCT01016483_1_mek,AE,AELLTCD,Lowest Level Term Code,Num,930,0,10000081,10003988,10013649,10016558,10021018,10024283,10029354,10037087,10043569,10051837,10069501
EMD_NCT01016483_1_mek,AE,AEDECOD,Dictionary-Derived Term,Char,930,0,Abdominal distension,Aspartate aminotransferase increased,Cholangitis,Dyspnoea,Gamma-glutamyltransferase increased,Hyponatraemia,Macular fibrosis,Neutropenia,Pyrexia,Thrombocytopenia,White blood cell count decreased
EMD_NCT01016483_1_mek,AE,AEPTCD,Preferred Term Code,Num,930,0,10000060,10003481,10010774,10016256,10020772,10024384,10029354,10033295,10042128,10047700,10075873
EMD_NCT01016483_1_mek,AE,AEHLT,High Level Term,Char,930,0,Acnes,Asthenic conditions,Diarrhoea (excl infective),Gastrointestinal and abdominal pains (excl oral and throat),Leukopenias NEC,Liver function analyses,Nausea and vomiting symptoms,Neutropenias,Potassium imbalance,Thrombocytopenias,White blood cell analyses
EMD_NCT01016483_1_mek,AE,AEHLTCD,High Level Term Code,Num,930,0,10000497,10003550,10012736,10017933,10024385,10024689,10028817,10030113,10042129,10047541,10076292
EMD_NCT01016483_1_mek,AE,AEHLGT,High Level Group Term,Char,930,0,Administration site reactions,Body temperature conditions,Epidermal and dermal conditions,Gastrointestinal signs and symptoms,General system disorders NEC,Hepatic and hepatobiliary disorders,Infections - pathogen unspecified,Platelet disorders,Purine and pyrimidine metabolism disorders,White blood cell disorders,White blood cell disorders
EMD_NCT01016483_1_mek,AE,AEHLGTCD,High Level Group Term Code,Num,930,0,10001316,10005908,10014982,10018012,10018073,10019809,10021879,10035534,10047438,10047954,10076290
EMD_NCT01016483_1_mek,AE,AEBODSYS,Body System or Organ Class,Char,930,0,Blood and lymphatic system disorders,Blood and lymphatic system disorders,Blood and lymphatic system disorders,Gastrointestinal disorders,Gastrointestinal disorders,General disorders and administration site conditions,General disorders and administration site conditions,Investigations,Investigations,Musculoskeletal and connective tissue disorders,Vascular disorders
EMD_NCT01016483_1_mek,AE,AEBDSYCD,Body System or Organ Class Code,Num,930,0,10005329,10005329,10005329,10017947,10017947,10018065,10018065,10022891,10022891,10028395,10047065
EMD_NCT01016483_1_mek,AE,AESOC,Primary System Organ Class,Char,930,0,Blood and lymphatic system disorders,Blood and lymphatic system disorders,Blood and lymphatic system disorders,Gastrointestinal disorders,Gastrointestinal disorders,General disorders and administration site conditions,General disorders and administration site conditions,Investigations,Investigations,Musculoskeletal and connective tissue disorders,Vascular disorders
EMD_NCT01016483_1_mek,AE,AESOCCD,Primary System Organ Class Code,Num,930,0,10005329,10005329,10005329,10017947,10017947,10018065,10018065,10022891,10022891,10028395,10047065
EMD_NCT01016483_1_mek,AE,AESER,Serious Event,Char,930,0,N,N,N,N,N,N,N,N,N,Y,Y
EMD_NCT01016483_1_mek,AE,AEACN,Action Taken with Study Treatment,Char,930,0,DOSE NOT CHANGED,DOSE NOT CHANGED,DOSE NOT CHANGED,DOSE NOT CHANGED,DOSE NOT CHANGED,DOSE NOT CHANGED,DOSE NOT CHANGED,DRUG INTERRUPTED,NOT APPLICABLE,NOT APPLICABLE,NOT APPLICABLE
EMD_NCT01016483_1_mek,AE,AEACNOTH,Other Action Taken,Char,694,236,LED TO STUDY TERMINATION,NONE,NONE,NONE,NONE,NONE,NONE,NONE,NONE,NONE,NONE
EMD_NCT01016483_1_mek,AE,AEREL,Causality,Char,928,2,RELATED,RELATED,UNRELATED,UNRELATED,UNRELATED,UNRELATED,UNRELATED,UNRELATED,UNRELATED,UNRELATED,UNRELATED
EMD_NCT01016483_1_mek,AE,AERELNST,Relationship to Non-Study Treatment,Char,930,0,CONCOMITANT MEDICATION,DISEASE UNDER STUDY,DISEASE UNDER STUDY,DISEASE UNDER STUDY,DISEASE UNDER STUDY,NONE,NONE,NONE,NONE,NONE,PROTOCOL PROCEDURE
EMD_NCT01016483_1_mek,AE,AEOUT,Outcome of Adverse Event,Char,780,150,FATAL,NOT RECOVERED/NOT RESOLVED,RECOVERED/RESOLVED,RECOVERED/RESOLVED,RECOVERED/RESOLVED,RECOVERED/RESOLVED,RECOVERED/RESOLVED,RECOVERED/RESOLVED,RECOVERED/RESOLVED,RECOVERED/RESOLVED,UNKNOWN
EMD_NCT01016483_1_mek,AE,AESCONG,Congenital Anomaly or Birth Defect,Char,0,930,,,,,,,,,,,
EMD_NCT01016483_1_mek,AE,AESDISAB,Persist or Signif Disability/Incapacity,Char,2,928,Y,,,,,,,,,,Y
EMD_NCT01016483_1_mek,AE,AESDTH,Results in Death,Char,23,907,Y,Y,Y,Y,Y,Y,Y,Y,Y,Y,Y
EMD_NCT01016483_1_mek,AE,AESHOSP,Requires or Prolongs Hospitalization,Char,40,890,Y,Y,Y,Y,Y,Y,Y,Y,Y,Y,Y
EMD_NCT01016483_1_mek,AE,AESLIFE,Is Life Threatening,Char,4,926,Y,,,,,Y,,,Y,,Y
EMD_NCT01016483_1_mek,AE,AESMIE,Other Medically Important Serious Event,Char,49,881,Y,Y,Y,Y,Y,Y,Y,Y,Y,Y,Y
EMD_NCT01016483_1_mek,AE,AECONTRT,Concomitant or Additional Trtmnt Given,Char,241,689,Y,Y,Y,Y,Y,Y,Y,Y,Y,Y,Y
EMD_NCT01016483_1_mek,AE,AETOXGR,Standard Toxicity Grade,Char,930,0,1,1,1,1,1,1,2,2,2,3,5
EMD_NCT01016483_1_mek,AE,ETCD,Element Code,Char,929,1,FU,PTP,TRT_PLA,TRT_PLA,TRT_PLA,TRT_PLA,TRT_PLA,TRT_PLA,TRT_PLA,TRT_PLA,UNPLAN
EMD_NCT01016483_1_mek,AE,ELEMENT,Description of Element,Char,927,3,Follow-up Period,Gemcitabine and Placebo,Gemcitabine and Placebo,Gemcitabine and Placebo,Gemcitabine and Placebo,Gemcitabine and Placebo,Gemcitabine and Placebo,Gemcitabine and Placebo,Gemcitabine and Placebo,Post Treatment Period,Screening
EMD_NCT01016483_1_mek,AE,EPOCH,Epoch,Char,929,1,FOLLOW-UP,POST TREATMENT,TREATMENT,TREATMENT,TREATMENT,TREATMENT,TREATMENT,TREATMENT,TREATMENT,TREATMENT,TREATMENT
EMD_NCT01016483_1_mek,AE,AESTDTC,Start Date/Time of Adverse Event,Char,930,0,2012-12-24,2013-05-12,2013-07-11,2013-08-12,2013-09-08,2013-10-07,2013-11-18,2014-01-08,2014-03-19,2014-06-15,2015-02-02
EMD_NCT01016483_1_mek,AE,AEENDTC,End Date/Time of Adverse Event,Char,930,0,******,******,2013-05-14,2013-07-28,2013-09-04,2013-10-04,2013-11-17,2014-01-08,2014-03-24,2014-06-24,2015-02-02
EMD_NCT01016483_1_mek,AE,AESTDY,Study Day of Start of Adverse Event,Num,923,7,-13,5,15,29,54,88,127,178,245,330,604
EMD_NCT01016483_1_mek,AE,AEENDY,Study Day of End of Adverse Event,Num,794,136,-8,15,29,44,84,113,157,211,271,348,604
EMD_NCT01016483_1_mek,AE,AEENRTPT,End Relative to Reference Time Point,Char,121,809,AFTER,AFTER,AFTER,AFTER,AFTER,AFTER,AFTER,AFTER,AFTER,AFTER,U
EMD_NCT01016483_1_mek,AE,AEENTPT,End Reference Time Point,Char,121,809,STUDY END,STUDY END,STUDY END,STUDY END,STUDY END,STUDY END,STUDY END,STUDY END,STUDY END,STUDY END,STUDY END
EMD_NCT01016483_1_mek,CM,STUDYID,Study Identifier,Char,995,0,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003
EMD_NCT01016483_1_mek,CM,DOMAIN,Domain Abbreviation,Char,995,0,CM,CM,CM,CM,CM,CM,CM,CM,CM,CM,CM
EMD_NCT01016483_1_mek,CM,USUBJID,Unique Subject Identifier,Char,995,0,1,3,11,17,21,25,31,34,38,41,44
EMD_NCT01016483_1_mek,CM,CMSEQ,Sequence Number,Num,995,0,1,3,5,8,10,13,16,20,26,34,71
EMD_NCT01016483_1_mek,CM,CMGRPID,Group ID,Char,4,991,0,,,,,0,,,0,,0
EMD_NCT01016483_1_mek,CM,CMSPID,Sponsor-Defined Identifier,Char,995,0,1,1,12,15,2,22,3,39,5,7,9
EMD_NCT01016483_1_mek,CM,CMTRT,"Reported Name of Drug, Med, or Therapy",Char,0,995,,,,,,,,,,,
EMD_NCT01016483_1_mek,CM,CMDECOD,Standardized Medication Name,Char,928,67,ACETYLCYSTEINE,AMOXICILLIN,DOMPERIDONE,GEMCITABINE,LOSARTAN POTASSIUM,MOVICOL                            /01749801/,ONDANSETRON,ONDANSETRON HYDROCHLORIDE,PANTOPRAZOLE SODIUM SESQUIHYDRATE,PREDNISONE,ZOLPIDEM TARTRATE
EMD_NCT01016483_1_mek,CM,CMCAT,Category for Medication,Char,995,0,CONCOMITANT MEDICATIONS,CONCOMITANT MEDICATIONS,CONCOMITANT MEDICATIONS,CONCOMITANT MEDICATIONS,CONCOMITANT MEDICATIONS,CONCOMITANT MEDICATIONS,CONCOMITANT MEDICATIONS,CONCOMITANT MEDICATIONS,CONCOMITANT MEDICATIONS,FURTHER ANTI-CANCER TREATMENT,PRIOR ANTI-CANCER TREATMENT
EMD_NCT01016483_1_mek,CM,CMSCAT,Subcategory for Medication,Char,30,965,DRUG THERAPY,DRUG THERAPY,SURGERY,SURGERY,SURGERY,SURGERY,SURGERY,SURGERY,SURGERY,SURGERY,SURGERY
EMD_NCT01016483_1_mek,CM,CMINDC,Indication,Char,0,995,,,,,,,,,,,
EMD_NCT01016483_1_mek,CM,CMDOSE,Dose per Administration,Num,837,158,0.18,1,4,5,8,15,25,50,100,500,40000
EMD_NCT01016483_1_mek,CM,CMDOSTXT,Dose Description,Char,33,962,"0,5",1-2,10-20,10MG/5MLS,1DOSE,20,30/500,NOT SPECIFIED,UNK,UNK,UNTIL 160
EMD_NCT01016483_1_mek,CM,CMDOSU,Dose Units,Char,872,123,Gy,OTHER,OTHER,mg,mg,mg,mg,mg,mg,mg,ug
EMD_NCT01016483_1_mek,CM,CMDOSFRQ,Dosing Frequency per Interval,Char,873,122,BID,BID,OTHER,PRN,PRN,QD,QD,QD,QD,QID,TID
EMD_NCT01016483_1_mek,CM,CMROUTE,Route of Administration,Char,873,122,INTRAMUSCULAR,INTRAVENOUS,INTRAVENOUS,INTRAVENOUS,ORAL,ORAL,ORAL,ORAL,ORAL,OTHER,TOPICAL
EMD_NCT01016483_1_mek,CM,ETCD,Element Code,Char,758,237,FU,MPTP,PTP,TRT_PLA,TRT_PLA,TRT_PLA,TRT_PLA,TRT_PLA,TRT_PLA,TRT_PLA,TRT_PLA
EMD_NCT01016483_1_mek,CM,ELEMENT,Description of Element,Char,758,237,Follow-up Period,Gemcitabine and Placebo,Gemcitabine and Placebo,Gemcitabine and Placebo,Gemcitabine and Placebo,Gemcitabine and Placebo,Gemcitabine and Placebo,Gemcitabine and Placebo,Pimasertib Monotherapy,Post Treatment Period,Screening
EMD_NCT01016483_1_mek,CM,EPOCH,Epoch,Char,758,237,FOLLOW-UP,MONOTHERAPY TREATMENT,POST TREATMENT,TREATMENT,TREATMENT,TREATMENT,TREATMENT,TREATMENT,TREATMENT,TREATMENT,TREATMENT
EMD_NCT01016483_1_mek,CM,CMSTDTC,Start Date/Time of Medication,Char,995,0,******,2012-12,2013-04-14,2013-06-04,2013-07-17,2013-08-14,2013-09-11,2013-10-16,2013-12-15,2014-03-19,2014-12-18
EMD_NCT01016483_1_mek,CM,CMENDTC,End Date/Time of Medication,Char,995,0,******,******,******,******,2013-05-21,2013-07-22,2013-09-02,2013-10-09,2013-12-11,2014-03-21,2014-12-18
EMD_NCT01016483_1_mek,CM,CMSTDY,Study Day of Start of Medication,Num,876,119,-3677,-25,1,8,21,40,71,99,152,239,477
EMD_NCT01016483_1_mek,CM,CMENDY,Study Day of End of Medication,Num,677,318,-319,8,15,28,37,68,96,127,197,267,450
EMD_NCT01016483_1_mek,CM,CMENRTPT,End Relative to Reference Time Point,Char,919,76,BEFORE,BEFORE,BEFORE,BEFORE,BEFORE,BEFORE,BEFORE,BEFORE,ONGOING,ONGOING,ONGOING
EMD_NCT01016483_1_mek,CM,CMENTPT,End Reference Time Point,Char,919,76,STUDY END,STUDY END,STUDY END,STUDY END,STUDY END,STUDY END,STUDY END,STUDY END,STUDY END,STUDY END,STUDY END
EMD_NCT01016483_1_mek,CO,STUDYID,Study Identifier,Char,276,0,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003
EMD_NCT01016483_1_mek,CO,DOMAIN,Domain Abbreviation,Char,276,0,CO,CO,CO,CO,CO,CO,CO,CO,CO,CO,CO
EMD_NCT01016483_1_mek,CO,RDOMAIN,Related Domain Abbreviation,Char,276,0,AE,AE,AE,AE,AE,AE,EG,EG,EG,ZO,ZO
EMD_NCT01016483_1_mek,CO,USUBJID,Unique Subject Identifier,Char,276,0,3,7,13,21,26,31,35,37,38,42,44
EMD_NCT01016483_1_mek,CO,COSEQ,Sequence Number,Num,276,0,1,1,2,3,4,6,7,10,15,25,41
EMD_NCT01016483_1_mek,CO,IDVAR,Identifying Variable,Char,276,0,AESEQ,AESEQ,AESEQ,AESEQ,AESEQ,AESEQ,EGGRPID,EGGRPID,EGGRPID,VISIT,VISIT
EMD_NCT01016483_1_mek,CO,IDVARVAL,Identifying Variable Value,Char,276,0,1,11,17,22,3,5,9,CYCLE 1 DAY 29,CYCLE 1 DAY 50,END OF TREATMENT 2013-09-19 ECG,UNSCHEDULED 2014-03-14 ECG
EMD_NCT01016483_1_mek,CO,COVAL,Comment,Char,0,276,,,,,,,,,,,
EMD_NCT01016483_1_mek,CO,COVAL1,Comment,Char,0,276,,,,,,,,,,,
EMD_NCT01016483_1_mek,CO,CODTC,Date/Time of Comment,Char,276,0,******,******,******,******,******,******,2012-12-30T13:50,2013-06-12T18:11,2013-08-11T08:52,2013-10-03,2014-08-19T16:40
EMD_NCT01016483_1_mek,CO,CODY,Study Day of Comment,Num,113,163,-33,-6,1,1,15,29,36,57,111,205,391
EMD_NCT01016483_1_mek,DATADICT,LIBNAME,Library Name,Char,658,0,ANON,ANON,ANON,ANON,ANON,ANON,ANON,ANON,ANON,ANON,ANON
EMD_NCT01016483_1_mek,DATADICT,MEMNAME,Library Member Name,Char,658,0,AE,CM,DV,IE,RS,SUPPDS,SUPPRS,TR,VS,XX,ZO
EMD_NCT01016483_1_mek,DATADICT,MEMLABEL,Data Set Label,Char,0,658,,,,,,,,,,,
EMD_NCT01016483_1_mek,DATADICT,TYPEMEM,Special Data Set Type (From TYPE=),Char,0,658,,,,,,,,,,,
EMD_NCT01016483_1_mek,DATADICT,NAME,Variable Name,Char,658,0,ACTARM,CMTRT,EGSTRESN,ETCD,LBDY,QLABEL,RSSEQ,TAETORD,USUBJID,VSSTRESU,ZOTESTCD
EMD_NCT01016483_1_mek,DATADICT,TYPE,Variable Type,Num,658,0,1,1,2,2,2,2,2,2,2,2,2
EMD_NCT01016483_1_mek,DATADICT,LENGTH,Variable Length,Num,658,0,1,2,8,8,8,10,19,25,33,50,200
EMD_NCT01016483_1_mek,DATADICT,VARNUM,Variable Number,Num,658,0,1,2,4,5,7,9,11,14,17,22,41
EMD_NCT01016483_1_mek,DATADICT,LABEL,Variable Label,Char,658,0,Action Taken with Study Treatment,Date/Time of Collection,Domain Abbreviation,Epoch,Identifying Variable Value,Other Medically Important Serious Event,Reason Not Performed,Sequence Number,Study Identifier,Unique Subject Identifier,Vital Signs Test Short Name
EMD_NCT01016483_1_mek,DATADICT,FORMAT,Variable Format,Char,0,658,,,,,,,,,,,
EMD_NCT01016483_1_mek,DATADICT,FORMATL,Format Length,Num,658,0,0,0,0,0,0,0,0,0,0,0,0
EMD_NCT01016483_1_mek,DATADICT,FORMATD,Number of Format Decimals,Num,658,0,0,0,0,0,0,0,0,0,0,0,0
EMD_NCT01016483_1_mek,DATADICT,INFORMAT,Variable Informat,Char,0,658,,,,,,,,,,,
EMD_NCT01016483_1_mek,DATADICT,INFORML,Informat Length,Num,658,0,0,0,0,0,0,0,0,0,0,0,0
EMD_NCT01016483_1_mek,DATADICT,INFORMD,Number of Informat Decimals,Num,658,0,0,0,0,0,0,0,0,0,0,0,0
EMD_NCT01016483_1_mek,DATADICT,JUST,Justification,Num,658,0,0,0,0,0,0,0,0,0,0,0,0
EMD_NCT01016483_1_mek,DATADICT,NPOS,Position in Buffer,Num,658,0,0,8,24,42,56,96,167,285,374,650,1745
EMD_NCT01016483_1_mek,DATADICT,NOBS,Observations in Data Set,Num,658,0,0,42,72,242,299,703,995,1486,8760,10398,23400
EMD_NCT01016483_1_mek,DATADICT,ENGINE,Engine Name,Char,658,0,V9,V9,V9,V9,V9,V9,V9,V9,V9,V9,V9
EMD_NCT01016483_1_mek,DATADICT,CRDATE,Create Date,Num,658,0,1922081485.4,1922081485.4,1922081485.5,1922081485.6,1922081485.7,1922081485.7,1922081485.8,1922081485.9,1922081485.9,1922081485.9,1922081486
EMD_NCT01016483_1_mek,DATADICT,MODATE,Last Modified Date,Num,658,0,1922081485.4,1922081485.4,1922081485.5,1922081485.6,1922081485.7,1922081485.7,1922081485.8,1922081485.9,1922081485.9,1922081485.9,1922081486
EMD_NCT01016483_1_mek,DATADICT,DELOBS,Deleted Observations in Data Set,Num,658,0,0,0,0,0,0,0,0,0,0,0,0
EMD_NCT01016483_1_mek,DATADICT,IDXUSAGE,Use of Variable in Indexes,Char,658,0,NONE,NONE,NONE,NONE,NONE,NONE,NONE,NONE,NONE,NONE,NONE
EMD_NCT01016483_1_mek,DATADICT,MEMTYPE,Library Member Type,Char,658,0,DATA,DATA,DATA,DATA,DATA,DATA,DATA,DATA,DATA,DATA,DATA
EMD_NCT01016483_1_mek,DATADICT,IDXCOUNT,Number of Indexes for Data Set,Num,658,0,0,0,0,0,0,0,0,0,0,0,0
EMD_NCT01016483_1_mek,DATADICT,PROTECT,Password Protection (Read Write Alter),Char,658,0,---,---,---,---,---,---,---,---,---,---,---
EMD_NCT01016483_1_mek,DATADICT,FLAGS,Update Flags (Protect Contribute Add),Char,658,0,---,---,---,---,---,---,---,---,---,---,---
EMD_NCT01016483_1_mek,DATADICT,COMPRESS,Compression Routine,Char,658,0,CHAR,CHAR,CHAR,CHAR,CHAR,CHAR,CHAR,CHAR,CHAR,CHAR,CHAR
EMD_NCT01016483_1_mek,DATADICT,REUSE,Reuse Space,Char,658,0,NO,NO,NO,NO,NO,NO,NO,NO,NO,NO,NO
EMD_NCT01016483_1_mek,DATADICT,SORTED,Sorted and/or Validated,Num,0,658,.,.,.,.,.,.,.,.,.,.,.
EMD_NCT01016483_1_mek,DATADICT,SORTEDBY,Position of Variable in Sortedby Clause,Num,0,658,.,.,.,.,.,.,.,.,.,.,.
EMD_NCT01016483_1_mek,DATADICT,CHARSET,Host Character Set,Char,0,658,,,,,,,,,,,
EMD_NCT01016483_1_mek,DATADICT,COLLATE,Collating Sequence,Char,0,658,,,,,,,,,,,
EMD_NCT01016483_1_mek,DATADICT,NODUPKEY,Sort Option: No Duplicate Keys,Char,658,0,NO,NO,NO,NO,NO,NO,NO,NO,NO,NO,NO
EMD_NCT01016483_1_mek,DATADICT,NODUPREC,Sort Option: No Duplicate Records,Char,658,0,NO,NO,NO,NO,NO,NO,NO,NO,NO,NO,NO
EMD_NCT01016483_1_mek,DATADICT,ENCRYPT,Encryption Routine,Char,658,0,NO,NO,NO,NO,NO,NO,NO,NO,NO,NO,NO
EMD_NCT01016483_1_mek,DATADICT,POINTOBS,Point to Observations,Char,658,0,YES,YES,YES,YES,YES,YES,YES,YES,YES,YES,YES
EMD_NCT01016483_1_mek,DATADICT,GENMAX,Maximum Number of Generations,Num,658,0,0,0,0,0,0,0,0,0,0,0,0
EMD_NCT01016483_1_mek,DATADICT,GENNUM,Generation Number,Num,0,658,.,.,.,.,.,.,.,.,.,.,.
EMD_NCT01016483_1_mek,DATADICT,GENNEXT,Next Generation Number,Num,0,658,.,.,.,.,.,.,.,.,.,.,.
EMD_NCT01016483_1_mek,DATADICT,TRANSCOD,Character Variables Transcoded,Char,658,0,YES,YES,YES,YES,YES,YES,YES,YES,YES,YES,YES
EMD_NCT01016483_1_mek,DM,STUDYID,Study Identifier,Char,44,0,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003
EMD_NCT01016483_1_mek,DM,DOMAIN,Domain Abbreviation,Char,44,0,DM,DM,DM,DM,DM,DM,DM,DM,DM,DM,DM
EMD_NCT01016483_1_mek,DM,USUBJID,Unique Subject Identifier,Char,44,0,1,4,8,13,17,22,26,30,35,39,44
EMD_NCT01016483_1_mek,DM,RFSTDTC,Subject Reference Start Date/Time,Char,44,0,******,2013-03-18,2013-04-27,2013-06-09T09:30,2013-06-29T08:20,2013-07-11T10:00,2013-07-22T10:50,2013-07-29T18:00,2013-09-03T12:30,2013-09-19T08:00,2013-10-27T11:30
EMD_NCT01016483_1_mek,DM,RFENDTC,Subject Reference End Date/Time,Char,44,0,******,2013-05-20T09:45,2013-07-16,2013-09-02,2013-09-25T21:00,2013-10-09T08:45,2013-11-11,2013-12-26T10:00,2014-02-11T21:20,2014-04-22T21:00,2015-02-15T22:20
EMD_NCT01016483_1_mek,DM,RFXSTDTC,Date/Time of First Study Treatment,Char,44,0,******,2013-03-18,2013-04-27,2013-06-09T09:30,2013-06-29T08:20,2013-07-11T10:00,2013-07-22T10:50,2013-07-29T18:00,2013-09-03T12:30,2013-09-19T08:00,2013-10-27T11:30
EMD_NCT01016483_1_mek,DM,RFXENDTC,Date/Time of Last Study Treatment,Char,44,0,******,2013-05-20T09:45,2013-07-16,2013-09-02,2013-09-25T21:00,2013-10-09T08:45,2013-11-11,2013-12-26T10:00,2014-02-11T21:20,2014-04-22T21:00,2015-02-15T22:20
EMD_NCT01016483_1_mek,DM,RFICDTC,Date/Time of Informed Consent,Char,44,0,2012-12-20,2013-03-05,2013-05-02,2013-06-04,2013-06-21,2013-07-02,2013-07-06,2013-07-17,2013-08-21,2013-09-09,2013-10-13
EMD_NCT01016483_1_mek,DM,RFPENDTC,Date/Time of End of Participation,Char,44,0,2013-03-23,2013-06-20,2013-08-11,2013-09-26,2013-10-10,2013-11-03,2013-11-25,2014-01-08,2014-03-16,2014-04-23,2015-03-16
EMD_NCT01016483_1_mek,DM,DTHDTC,Date/Time of Death,Char,44,0,******,******,2013-07-22,2013-09-27,2013-11-19,2013-12-21,2014-03-12,2014-04-16,2014-06-11,2014-09-26,2015-03-05
EMD_NCT01016483_1_mek,DM,DTHFL,Subject Death Flag,Char,44,0,N,N,Y,Y,Y,Y,Y,Y,Y,Y,Y
EMD_NCT01016483_1_mek,DM,SITEID,Study Site Identifier,Char,44,0,1,2,4,8,8,10,12,14,18,20,21
EMD_NCT01016483_1_mek,DM,BRTHDTC,Date/Time of Birth,Char,44,0,1932,1939,1942,1947,1947,1948,1950,1953,1957,1960,1972
EMD_NCT01016483_1_mek,DM,AGE,Age,Num,44,0,40,51,54,58,62,64,65,66,67,71,81
EMD_NCT01016483_1_mek,DM,AGEU,Age Units,Char,44,0,YEARS,YEARS,YEARS,YEARS,YEARS,YEARS,YEARS,YEARS,YEARS,YEARS,YEARS
EMD_NCT01016483_1_mek,DM,SEX,Sex,Char,44,0,F,F,F,F,F,F,M,M,M,M,M
EMD_NCT01016483_1_mek,DM,RACE,Race,Char,43,1,WHITE,WHITE,WHITE,WHITE,WHITE,WHITE,WHITE,WHITE,WHITE,WHITE,WHITE
EMD_NCT01016483_1_mek,DM,ARMCD,Planned Arm Code,Char,44,0,A,A,A,A,A,A,A,A,A,A,A
EMD_NCT01016483_1_mek,DM,ARM,Description of Planned Arm,Char,44,0,Arm 1: Gemcitabine and Placebo,Arm 1: Gemcitabine and Placebo,Arm 1: Gemcitabine and Placebo,Arm 1: Gemcitabine and Placebo,Arm 1: Gemcitabine and Placebo,Arm 1: Gemcitabine and Placebo,Arm 1: Gemcitabine and Placebo,Arm 1: Gemcitabine and Placebo,Arm 1: Gemcitabine and Placebo,Arm 1: Gemcitabine and Placebo,Arm 1: Gemcitabine and Placebo
EMD_NCT01016483_1_mek,DM,ACTARMCD,Actual Arm Code,Char,44,0,A,A,A,A,A,A,A,A,A,A,NOTTRT
EMD_NCT01016483_1_mek,DM,ACTARM,Description of Actual Arm,Char,44,0,Arm 1: Gemcitabine and Placebo,Arm 1: Gemcitabine and Placebo,Arm 1: Gemcitabine and Placebo,Arm 1: Gemcitabine and Placebo,Arm 1: Gemcitabine and Placebo,Arm 1: Gemcitabine and Placebo,Arm 1: Gemcitabine and Placebo,Arm 1: Gemcitabine and Placebo,Arm 1: Gemcitabine and Placebo,Arm 1: Gemcitabine and Placebo,Not Treated
EMD_NCT01016483_1_mek,DM,COUNTRY,Country,Char,44,0,1,2,3,3,4,4,4,5,7,7,7
EMD_NCT01016483_1_mek,DM,ETCD,Element Code,Char,44,0,SCRN,SCRN,SCRN,SCRN,SCRN,SCRN,SCRN,SCRN,SCRN,SCRN,SCRN
EMD_NCT01016483_1_mek,DM,ELEMENT,Description of Element,Char,44,0,Screening,Screening,Screening,Screening,Screening,Screening,Screening,Screening,Screening,Screening,Screening
EMD_NCT01016483_1_mek,DM,EPOCH,Epoch,Char,44,0,SCREENING,SCREENING,SCREENING,SCREENING,SCREENING,SCREENING,SCREENING,SCREENING,SCREENING,SCREENING,SCREENING
EMD_NCT01016483_1_mek,DM,DMDTC,Date/Time of Collection,Char,44,0,2012-12-20,2013-03-05,2013-05-02,2013-06-04,2013-06-23,2013-07-03,2013-07-11,2013-07-28,2013-08-25,2013-09-12,2013-10-16
EMD_NCT01016483_1_mek,DM,DMDY,Study Day of Collection,Num,43,1,-29,-20,-16,-13,-10,-8,-7,-6,-6,-2,-1
EMD_NCT01016483_1_mek,DS,STUDYID,Study Identifier,Char,299,0,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003
EMD_NCT01016483_1_mek,DS,DOMAIN,Domain Abbreviation,Char,299,0,DS,DS,DS,DS,DS,DS,DS,DS,DS,DS,DS
EMD_NCT01016483_1_mek,DS,USUBJID,Unique Subject Identifier,Char,299,0,1,6,10,15,19,23,28,33,37,41,44
EMD_NCT01016483_1_mek,DS,DSSEQ,Sequence Number,Num,299,0,1,1,2,3,3,4,5,5,6,7,11
EMD_NCT01016483_1_mek,DS,DSREFID,Reference ID,Char,44,255,2002,2008,2016,5001,6003,6011,7001,7009,7020,8004,9005
EMD_NCT01016483_1_mek,DS,DSTERM,Reported Term for the Disposition Event,Char,0,299,,,,,,,,,,,
EMD_NCT01016483_1_mek,DS,DSDECOD,Standardized Disposition Term,Char,299,0,ADVERSE EVENT,DEATH,DEATH,INFORMED CONSENT OBTAINED,INFORMED CONSENT OBTAINED,PGX INFORMED CONSENT OBTAINED,PROGRESSIVE DISEASE,PROGRESSIVE DISEASE,PROGRESSIVE DISEASE,RANDOMIZED,WITHDRAWAL BY SUBJECT
EMD_NCT01016483_1_mek,DS,DSCAT,Category for Disposition Event,Char,299,0,DISPOSITION EVENT,DISPOSITION EVENT,DISPOSITION EVENT,DISPOSITION EVENT,DISPOSITION EVENT,DISPOSITION EVENT,PROTOCOL MILESTONE,PROTOCOL MILESTONE,PROTOCOL MILESTONE,PROTOCOL MILESTONE,PROTOCOL MILESTONE
EMD_NCT01016483_1_mek,DS,DSSCAT,Subcategory for Disposition Event,Char,245,54,DEATH,DEATH,END OF STUDY,END OF STUDY,END OF TREATMENT,END OF TREATMENT,MONOTHERAPY END OF STUDY,STUDY TREATMENT,STUDY TREATMENT,STUDY TREATMENT,STUDY TREATMENT
EMD_NCT01016483_1_mek,DS,ETCD,Element Code,Char,155,144,FU,FU,MONOTHER,MPTP,PTP,PTP,PTP,PTP,TRT_PLA,TRT_PLA,TRT_PLA
EMD_NCT01016483_1_mek,DS,ELEMENT,Description of Element,Char,155,144,Follow-up Period,Follow-up Period,Gemcitabine and Placebo,Gemcitabine and Placebo,Gemcitabine and Placebo,Monotherapy Post Treatment Period,Pimasertib Monotherapy,Post Treatment Period,Post Treatment Period,Post Treatment Period,Post Treatment Period
EMD_NCT01016483_1_mek,DS,EPOCH,Epoch,Char,155,144,FOLLOW-UP,FOLLOW-UP,MONOTHERAPY POST TREATMENT,MONOTHERAPY TREATMENT,POST TREATMENT,POST TREATMENT,POST TREATMENT,POST TREATMENT,TREATMENT,TREATMENT,TREATMENT
EMD_NCT01016483_1_mek,DS,DSDTC,Date/Time of Collection,Char,299,0,******,******,2013-04-12,2013-06-14,2013-07-11,2013-08-03,2013-09-07,2013-10-13,2013-11-06,2014-02-11,2015-03-16
EMD_NCT01016483_1_mek,DS,DSSTDTC,Start Date/Time of Disposition Event,Char,299,0,******,******,2013-04-06,2013-06-20,2013-07-16,2013-09-02,2013-10-08,2013-11-14,2014-01-23,2014-04-16,2015-03-16
EMD_NCT01016483_1_mek,DS,DSDY,Study Day of Collection,Num,255,44,-29,-7,1,1,1,1,52,86,143,231,646
EMD_NCT01016483_1_mek,DS,DSSTDY,Study Day of Start of Disposition Event,Num,251,48,-33,-15,-8,-6,29,56,91,148,202,284,646
EMD_NCT01016483_1_mek,DV,STUDYID,Study Identifier,Char,719,0,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003
EMD_NCT01016483_1_mek,DV,DOMAIN,Domain Abbreviation,Char,719,0,DV,DV,DV,DV,DV,DV,DV,DV,DV,DV,DV
EMD_NCT01016483_1_mek,DV,USUBJID,Unique Subject Identifier,Char,719,0,1,8,11,17,21,27,34,38,39,41,44
EMD_NCT01016483_1_mek,DV,DVSEQ,Sequence Number,Num,719,0,1,2,4,7,10,14,20,28,37,54,85
EMD_NCT01016483_1_mek,DV,DVTERM,Protocol Deviation Term,Char,0,719,,,,,,,,,,,
EMD_NCT01016483_1_mek,DV,DVCAT,Category for Protocol Deviation,Char,718,1,MAJOR,MINOR,MINOR,MINOR,MINOR,MINOR,MINOR,MINOR,MINOR,MINOR,MINOR
EMD_NCT01016483_1_mek,DV,ETCD,Element Code,Char,559,160,FU,FU,FU,MPTP,PTP,TRT_PLA,TRT_PLA,TRT_PLA,TRT_PLA,TRT_PLA,UNPLAN
EMD_NCT01016483_1_mek,DV,ELEMENT,Description of Element,Char,557,162,Follow-up Period,Follow-up Period,Follow-up Period,Gemcitabine and Placebo,Gemcitabine and Placebo,Gemcitabine and Placebo,Gemcitabine and Placebo,Gemcitabine and Placebo,Monotherapy Post Treatment Period,Monotherapy Post Treatment Period,Post Treatment Period
EMD_NCT01016483_1_mek,DV,EPOCH,Epoch,Char,559,160,FOLLOW-UP,FOLLOW-UP,FOLLOW-UP,MONOTHERAPY POST TREATMENT,POST TREATMENT,TREATMENT,TREATMENT,TREATMENT,TREATMENT,TREATMENT,TREATMENT
EMD_NCT01016483_1_mek,DV,DVSTDTC,Start Date/Time of Deviation,Char,719,0,******,2013-07-24,2013-08-01,2013-10-13,2013-11-15,2013-12-14,2014-01-04,2014-01-21,2014-02-21,2014-05-06,2014-11-18
EMD_NCT01016483_1_mek,DV,DVSTDY,Study Day of Start of Deviation,Num,713,6,8,43,101,104,128,162,214,231,260,309,486
EMD_NCT01016483_1_mek,EG,STUDYID,Study Identifier,Char,10398,0,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003
EMD_NCT01016483_1_mek,EG,DOMAIN,Domain Abbreviation,Char,10398,0,EG,EG,EG,EG,EG,EG,EG,EG,EG,EG,EG
EMD_NCT01016483_1_mek,EG,USUBJID,Unique Subject Identifier,Char,10398,0,1,5,8,14,20,23,27,34,37,41,44
EMD_NCT01016483_1_mek,EG,EGSEQ,Sequence Number,Num,10398,0,1,24,49,73,99,128,164,208,262,338,571
EMD_NCT01016483_1_mek,EG,EGGRPID,Group ID,Char,0,10398,,,,,,,,,,,
EMD_NCT01016483_1_mek,EG,EGTESTCD,ECG Test or Examination Short Name,Char,10398,0,CONDUCT,HRMEAN,INTP,INTP,PRMEAN,QRS,QT,QTCB,QTCF,RRMEAN,TWAVE
EMD_NCT01016483_1_mek,EG,EGTEST,ECG Test or Examination Name,Char,10398,0,Conduction Finding,Interpretation,QRS Interval,QRS Interval,QT Interval,QTcB - Bazett's Correction Formula,QTcF - Fridericia's Correction Formula,Summary (Mean) Heart Rate,Summary (Mean) PR Duration,Summary (Mean) RR Duration,T Waves Finding
EMD_NCT01016483_1_mek,EG,EGORRES,Result or Finding in Original Units,Char,9780,618,100,155,377,408,430,47,73,84,95,LOW VOLTAGE,VENTRICULAR PREMATURE COMPLEXES
EMD_NCT01016483_1_mek,EG,EGORRESU,Original Units,Char,8080,2318,BEATS/MIN,BEATS/MIN,msec,msec,msec,msec,msec,msec,msec,msec,msec
EMD_NCT01016483_1_mek,EG,EGSTRESC,Character Result/Finding in Std Format,Char,9780,618,100,155,377,408,430,47,73,84,95,LOW VOLTAGE,VENTRICULAR PREMATURE COMPLEXES
EMD_NCT01016483_1_mek,EG,EGSTRESN,Numeric Result/Finding in Standard Units,Num,8080,2318,37,77,90,130,177,386,408,427,449,767,1610
EMD_NCT01016483_1_mek,EG,EGSTRESU,Standard Units,Char,8080,2318,BEATS/MIN,BEATS/MIN,msec,msec,msec,msec,msec,msec,msec,msec,msec
EMD_NCT01016483_1_mek,EG,EGSTAT,Completion Status,Char,618,9780,NOT DONE,NOT DONE,NOT DONE,NOT DONE,NOT DONE,NOT DONE,NOT DONE,NOT DONE,NOT DONE,NOT DONE,NOT DONE
EMD_NCT01016483_1_mek,EG,EGREASND,Reason ECG Not Performed,Char,618,9780,NOT COLLECTED ON CRF,NOT COLLECTED ON CRF,NOT COLLECTED ON CRF,NOT COLLECTED ON CRF,NOT COLLECTED ON CRF,NOT COLLECTED ON CRF,NOT COLLECTED ON CRF,NOT COLLECTED ON CRF,NOT COLLECTED ON CRF,NOT COLLECTED ON CRF,NOT COLLECTED ON CRF
EMD_NCT01016483_1_mek,EG,EGBLFL,Baseline Flag,Char,377,10021,Y,Y,Y,Y,Y,Y,Y,Y,Y,Y,Y
EMD_NCT01016483_1_mek,EG,VISITNUM,Visit Number,Num,10398,0,1,101,102,108,115,122,136,147,401,1201,26777
EMD_NCT01016483_1_mek,EG,VISIT,Visit Name,Char,10398,0,CYCLE 1 DAY 1,CYCLE 1 DAY 1,CYCLE 1 DAY 15,CYCLE 1 DAY 22,CYCLE 1 DAY 29,CYCLE 1 DAY 36,CYCLE 1 DAY 8,CYCLE 10 DAY 1,CYCLE 3 DAY 1,END OF TREATMENT,SCREENING
EMD_NCT01016483_1_mek,EG,VISITDY,Planned Study Day of Visit,Num,9981,417,-28,1,2,8,15,22,29,43,85,225,2085
EMD_NCT01016483_1_mek,EG,ETCD,Element Code,Char,9780,618,MONOTHER,SCRN,TRT_PLA,TRT_PLA,TRT_PLA,TRT_PLA,TRT_PLA,TRT_PLA,TRT_PLA,TRT_PLA,UNPLAN
EMD_NCT01016483_1_mek,EG,ELEMENT,Description of Element,Char,9756,642,Gemcitabine and Placebo,Gemcitabine and Placebo,Gemcitabine and Placebo,Gemcitabine and Placebo,Gemcitabine and Placebo,Gemcitabine and Placebo,Gemcitabine and Placebo,Gemcitabine and Placebo,Gemcitabine and Placebo,Monotherapy Post Treatment Period,Screening
EMD_NCT01016483_1_mek,EG,EPOCH,Epoch,Char,9780,618,MONOTHERAPY POST TREATMENT,SCREENING,TREATMENT,TREATMENT,TREATMENT,TREATMENT,TREATMENT,TREATMENT,TREATMENT,TREATMENT,TREATMENT
EMD_NCT01016483_1_mek,EG,EGDTC,Date/Time of ECG,Char,10398,0,******,2013-03-10T09:51,2013-05-09T09:07,2013-06-14T13:58,2013-07-12T12:57,2013-08-01T09:41,2013-08-22T13:00,2013-09-17T09:55,2013-10-27T08:30,2014-01-15T09:02,2015-02-16T09:27
EMD_NCT01016483_1_mek,EG,EGDY,Study Day of ECG,Num,9780,618,-21,1,2,8,15,22,36,47,85,180,618
EMD_NCT01016483_1_mek,EG,EGTPT,Planned Time Point Name,Char,9532,866,1 HOUR POST DOSE,1 HOUR POST DOSE,1 HOUR POST DOSE,1 HOUR POST DOSE,2 HOURS POST DOSE,4 HOURS POST DOSE,4 HOURS POST DOSE,PRE-DOSE,PRE-DOSE,PRE-DOSE,PRE-DOSE
EMD_NCT01016483_1_mek,EG,EGTPTNUM,Planned Time Point Number,Num,9532,866,0,0,0,0,100,100,100,100,200,400,400
EMD_NCT01016483_1_mek,EG,EGELTM,Planned Elapsed Time from Time Point Ref,Char,9532,866,-PT5M,-PT5M,-PT5M,-PT5M,PT1H,PT1H,PT1H,PT1H,PT2H,PT4H,PT4H
EMD_NCT01016483_1_mek,EG,EGTPTREF,Time Point Reference,Char,9532,866,AM DOSE OF PIMASERTIB,AM DOSE OF PLACEBO,AM DOSE OF PLACEBO,AM DOSE OF PLACEBO,AM DOSE OF PLACEBO,AM DOSE OF PLACEBO,AM DOSE OF PLACEBO,AM DOSE OF PLACEBO,AM DOSE OF PLACEBO,AM DOSE OF PLACEBO,AM DOSE OF PLACEBO
EMD_NCT01016483_1_mek,EG,EGRFTDTC,Date/Time of Reference Time Point,Char,10398,0,******,******,******,2013-04-26T10:05,2013-06-13T13:00,2013-07-16T10:48,2013-08-06T12:00,2013-09-02T10:15,2013-09-30T11:00,2013-12-22T11:05,2015-01-19T10:20
EMD_NCT01016483_1_mek,EX,STUDYID,Study Identifier,Char,11309,0,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003
EMD_NCT01016483_1_mek,EX,DOMAIN,Domain Abbreviation,Char,11309,0,EX,EX,EX,EX,EX,EX,EX,EX,EX,EX,EX
EMD_NCT01016483_1_mek,EX,USUBJID,Unique Subject Identifier,Char,11309,0,1,5,5,8,16,21,26,33,37,41,44
EMD_NCT01016483_1_mek,EX,EXSEQ,Sequence Number,Num,11309,0,1,28,60,96,138,190,249,336,454,649,1301
EMD_NCT01016483_1_mek,EX,EXGRPID,Group ID,Char,11309,0,GEMCITABINE CYCLE 1,PIMASERTIB CYCLE 2,PLACEBO CYCLE 1,PLACEBO CYCLE 1,PLACEBO CYCLE 1,PLACEBO CYCLE 14,PLACEBO CYCLE 2,PLACEBO CYCLE 3,PLACEBO CYCLE 5,PLACEBO CYCLE 6,PLACEBO CYCLE 9
EMD_NCT01016483_1_mek,EX,EXTRT,Name of Actual Treatment,Char,11309,0,GEMCITABINE,PIMASERTIB,PLACEBO,PLACEBO,PLACEBO,PLACEBO,PLACEBO,PLACEBO,PLACEBO,PLACEBO,PLACEBO
EMD_NCT01016483_1_mek,EX,EXCAT,Category for Treatment,Char,11309,0,GEMCITABINE ADMINISTRATION,STUDY TREATMENT PIMASERTIB ADMINISTRATION,STUDY TREATMENT PLACEBO ADMINISTRATION,STUDY TREATMENT PLACEBO ADMINISTRATION,STUDY TREATMENT PLACEBO ADMINISTRATION,STUDY TREATMENT PLACEBO ADMINISTRATION,STUDY TREATMENT PLACEBO ADMINISTRATION,STUDY TREATMENT PLACEBO ADMINISTRATION,STUDY TREATMENT PLACEBO ADMINISTRATION,STUDY TREATMENT PLACEBO ADMINISTRATION,STUDY TREATMENT PLACEBO ADMINISTRATION
EMD_NCT01016483_1_mek,EX,EXSCAT,Subcategory for Treatment,Char,11309,0,MONOTHERAPY,PHASE II,PHASE II,PHASE II,PHASE II,PHASE II,PHASE II,PHASE II,PHASE II,PHASE II,PHASE II
EMD_NCT01016483_1_mek,EX,EXDOSU,Dose Units,Char,11229,80,mg,mg,mg,mg,mg,mg,mg,mg,mg,mg,mg
EMD_NCT01016483_1_mek,EX,EXDOSFRM,Dose Form,Char,11309,0,CAPSULE,CAPSULE,CAPSULE,CAPSULE,CAPSULE,CAPSULE,CAPSULE,CAPSULE,CAPSULE,CAPSULE,SOLUTION
EMD_NCT01016483_1_mek,EX,EXDOSFRQ,Dosing Frequency per Interval,Char,11309,0,BID,BID,BID,BID,BID,BID,BID,BID,BID,BID,Q7D
EMD_NCT01016483_1_mek,EX,EXDOSTOT,Total Daily Dose,Num,11229,80,0,0,0,0,0,0,0,0,0,0,2050
EMD_NCT01016483_1_mek,EX,EXDOSRGM,Intended Dose Regimen,Char,11309,0,"DAYS 1, 8, 15, 22, 29, 36 AND 43 FOLLOWED BY 1 WEEK REST THEN ON DAYS 1, 8 AND 15 OF A 28-DAY CYCLE","TWICE DAILY, CONTINUOUSLY WITHOUT A BREAK FOR A 28-DAY CYCLE","TWICE DAILY, CONTINUOUSLY WITHOUT A BREAK FOR A 28-DAY CYCLE","TWICE DAILY, CONTINUOUSLY WITHOUT A BREAK FOR A 28-DAY CYCLE","TWICE DAILY, CONTINUOUSLY WITHOUT A BREAK FOR A 28-DAY CYCLE","TWICE DAILY, CONTINUOUSLY WITHOUT A BREAK FOR A 28-DAY CYCLE","TWICE DAILY, CONTINUOUSLY WITHOUT A BREAK FOR A 28-DAY CYCLE","TWICE DAILY, CONTINUOUSLY WITHOUT A BREAK FOR A 28-DAY CYCLE","TWICE DAILY, CONTINUOUSLY WITHOUT A BREAK FOR A 28-DAY CYCLE","TWICE DAILY, CONTINUOUSLY WITHOUT A BREAK FOR A 28-DAY CYCLE","TWICE DAILY, DAYS 1 TO 28 CONTINUOUSLY WITHOUT A BREAK FOR A 28-DAY CYCLE"
EMD_NCT01016483_1_mek,EX,EXROUTE,Route of Administration,Char,11309,0,INTRAVENOUS,ORAL,ORAL,ORAL,ORAL,ORAL,ORAL,ORAL,ORAL,ORAL,ORAL
EMD_NCT01016483_1_mek,EX,EXADJ,Reason for Dose Adjustment,Char,11253,56,ADVERSE EVENT,NO CHANGE,NO CHANGE,NO CHANGE,NO CHANGE,NO CHANGE,NO CHANGE,NO CHANGE,NO CHANGE,NO CHANGE,OTHER
EMD_NCT01016483_1_mek,EX,ETCD,Element Code,Char,11309,0,MONOTHER,TRT_PLA,TRT_PLA,TRT_PLA,TRT_PLA,TRT_PLA,TRT_PLA,TRT_PLA,TRT_PLA,TRT_PLA,UNPLAN
EMD_NCT01016483_1_mek,EX,ELEMENT,Description of Element,Char,11278,31,Gemcitabine and Placebo,Gemcitabine and Placebo,Gemcitabine and Placebo,Gemcitabine and Placebo,Gemcitabine and Placebo,Gemcitabine and Placebo,Gemcitabine and Placebo,Gemcitabine and Placebo,Gemcitabine and Placebo,Gemcitabine and Placebo,Post Treatment Period
EMD_NCT01016483_1_mek,EX,EPOCH,Epoch,Char,11309,0,MONOTHERAPY TREATMENT,TREATMENT,TREATMENT,TREATMENT,TREATMENT,TREATMENT,TREATMENT,TREATMENT,TREATMENT,TREATMENT,TREATMENT
EMD_NCT01016483_1_mek,EX,EXSTDTC,Start Date/Time of Treatment,Char,11309,0,2012-12-30T11:50,2013-06-14T22:00,2013-07-27T09:00,2013-08-24T18:30,2013-09-22,2013-10-23T15:00,2013-11-26T09:00,2014-01-06T08:00,2014-03-03T10:15,2014-06-23T10:07,2015-02-15T22:20
EMD_NCT01016483_1_mek,EX,EXENDTC,End Date/Time of Treatment,Char,11309,0,2012-12-30T11:50,2013-06-14T22:00,2013-07-27T09:00,2013-08-24T18:30,2013-09-22,2013-10-23T15:00,2013-11-26T09:00,2014-01-06T08:00,2014-03-03T10:45,2014-06-23T10:25,2015-02-15T22:20
EMD_NCT01016483_1_mek,EX,EXSTDY,Study Day of Start of Treatment,Num,11309,0,1,14,29,47,71,97,128,168,223,313,617
EMD_NCT01016483_1_mek,EX,EXENDY,Study Day of End of Treatment,Num,11309,0,1,14,29,47,71,97,128,168,223,313,617
EMD_NCT01016483_1_mek,LB,STUDYID,Study Identifier,Char,23400,0,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003
EMD_NCT01016483_1_mek,LB,DOMAIN,Domain Abbreviation,Char,23400,0,LB,LB,LB,LB,LB,LB,LB,LB,LB,LB,LB
EMD_NCT01016483_1_mek,LB,USUBJID,Unique Subject Identifier,Char,23400,0,1,5,7,11,18,21,26,33,37,40,44
EMD_NCT01016483_1_mek,LB,LBSEQ,Sequence Number,Num,23400,0,1,54,109,174,247,337,447,608,826,1200,2332
EMD_NCT01016483_1_mek,LB,LBTESTCD,Lab Test or Examination Short Name,Char,23400,0,ALB,ALT,BILI,CA19_9AG,EOSLE,HGB,LYM,MONOLE,PLAT,SODIUM,WBC
EMD_NCT01016483_1_mek,LB,LBTEST,Lab Test or Examination Name,Char,23400,0,Alanine Aminotransferase,Alkaline Phosphatase,Bilirubin,Cancer Antigen 19-9,Eosinophils/Leukocytes,Glucose,Leukocytes,Magnesium,Phosphate,Protein,Urate
EMD_NCT01016483_1_mek,LB,LBCAT,Category for Lab Test,Char,23400,0,BIOCHEMISTRY,BIOCHEMISTRY,BIOCHEMISTRY,BIOCHEMISTRY,BIOCHEMISTRY,BIOCHEMISTRY,BIOCHEMISTRY,HEMATOLOGY,HEMATOLOGY,HEMATOLOGY,TUMOR MARKER
EMD_NCT01016483_1_mek,LB,LBSCAT,Subcategory for Lab Test,Char,201,23199,ARCHIVED TUMOR BIOPSY,ARCHIVED TUMOR BIOPSY,ARCHIVED TUMOR BIOPSY,ARCHIVED TUMOR BIOPSY,ARCHIVED TUMOR BIOPSY,ARCHIVED TUMOR BIOPSY,ARCHIVED TUMOR BIOPSY,ARCHIVED TUMOR BIOPSY,ARCHIVED TUMOR BIOPSY,ARCHIVED TUMOR BIOPSY,FRESH TUMOR BIOPSY
EMD_NCT01016483_1_mek,LB,LBORRES,Result or Finding in Original Units,Char,22316,1084,0,0.56,1.22,122,19,245,3.93,4.32,5.7,7.4,Q61L
EMD_NCT01016483_1_mek,LB,LBORRESU,Original Units,Char,22122,1278,%,10^3/uL,10^9/l,10^9/l,IU/L,IU/L,g/dL,mcmol/L,mmol/L,mmol/L,mmol/L
EMD_NCT01016483_1_mek,LB,LBORNRLO,Reference Range Lower Limit in Orig Unit,Char,22077,1323,0,0,0.00,0.7,10,136,2.15,3.5,35,45,90
EMD_NCT01016483_1_mek,LB,LBORNRHI,Reference Range Upper Limit in Orig Unit,Char,22077,1323,0.065,1,100,152,20.5,35,416,5.2,53,8,<40
EMD_NCT01016483_1_mek,LB,LBSTRESC,Character Result/Finding in Std Format,Char,22316,1084,0,0.7,1.54,137,2.29,276,33,4.87,513,7.6,Q61L
EMD_NCT01016483_1_mek,LB,LBSTRESN,Numeric Result/Finding in Standard Units,Num,22122,1278,0,0.7,1.5,3.5,5.34,14,40,69,121,224,155529.6
EMD_NCT01016483_1_mek,LB,LBSTRESU,Standard Units,Char,22122,1278,%,10^9/L,10^9/L,10^9/L,IU/L,IU/L,g/L,mmol/L,mmol/L,umol/L,umol/L
EMD_NCT01016483_1_mek,LB,LBSTNRLO,Reference Range Lower Limit-Std Units,Num,22077,1323,0,0,0,0.8,2,3.5,4.1,32,62,135,240
EMD_NCT01016483_1_mek,LB,LBSTNRHI,Reference Range Upper Limit-Std Units,Num,22077,1323,0.065,1,2.63,5.551,8,20.52,48,83.98,145,306,600
EMD_NCT01016483_1_mek,LB,LBNRIND,Reference Range Indicator,Char,7336,16064,HIGH,HIGH,HIGH,HIGH,HIGH,LOW,LOW,LOW,LOW,LOW,LOW
EMD_NCT01016483_1_mek,LB,LBRESCAT,Result Category,Char,192,23208,MUTATION,MUTATION,WILDTYPE,WILDTYPE,WILDTYPE,WILDTYPE,WILDTYPE,WILDTYPE,WILDTYPE,WILDTYPE,WILDTYPE
EMD_NCT01016483_1_mek,LB,LBSTAT,Completion Status,Char,1075,22325,NOT DONE,NOT DONE,NOT DONE,NOT DONE,NOT DONE,NOT DONE,NOT DONE,NOT DONE,NOT DONE,NOT DONE,NOT DONE
EMD_NCT01016483_1_mek,LB,LBREASND,Reason Test Not Done,Char,1075,22325,NOT COLLECTED ON CRF,NOT COLLECTED ON CRF,NOT COLLECTED ON CRF,NOT COLLECTED ON CRF,NOT COLLECTED ON CRF,NOT COLLECTED ON CRF,NOT COLLECTED ON CRF,NOT COLLECTED ON CRF,NOT COLLECTED ON CRF,NOT COLLECTED ON CRF,SURGICALLY STERILIZED
EMD_NCT01016483_1_mek,LB,LBSPEC,Specimen Type,Char,23400,0,BLOOD,BLOOD,BLOOD,BLOOD,SERUM,SERUM,SERUM,SERUM,SERUM,SERUM,TUMOR TISSUE
EMD_NCT01016483_1_mek,LB,LBLOC,Location Used for the Measurement,Char,192,23208,EXON 1 - CODON 12,EXON 1 - CODON 12,EXON 1 - CODON 13,EXON 1 - CODON 13,EXON 1 - CODON 61,EXON 1 - CODON 61,EXON 15 - CODON 600,EXON 20,EXON 20,EXON 9,EXON 9
EMD_NCT01016483_1_mek,LB,LBMETHOD,Method of Test or Examination,Char,192,23208,PYROSEQUENCING,PYROSEQUENCING,PYROSEQUENCING,PYROSEQUENCING,PYROSEQUENCING,PYROSEQUENCING,PYROSEQUENCING,PYROSEQUENCING,PYROSEQUENCING,PYROSEQUENCING,PYROSEQUENCING
EMD_NCT01016483_1_mek,LB,LBBLFL,Baseline Flag,Char,1203,22197,Y,Y,Y,Y,Y,Y,Y,Y,Y,Y,Y
EMD_NCT01016483_1_mek,LB,VISITNUM,Visit Number,Num,23400,0,1,108,122,136,215,315,501,701,1008,16677.02,26977.01
EMD_NCT01016483_1_mek,LB,VISIT,Visit Name,Char,23400,0,CYCLE 1 DAY 1,CYCLE 1 DAY 22,CYCLE 1 DAY 43,CYCLE 11 DAY 15,CYCLE 2 DAY 1,CYCLE 3 DAY 1,CYCLE 4 DAY 15,CYCLE 6 DAY 1,CYCLE 8 DAY 8,MONOTHERAPY CYCLE 4 DAY 1 UNSCHEDULED 1,TREATMENT TERMINATION UNSCHEDULED 3
EMD_NCT01016483_1_mek,LB,VISITDY,Planned Study Day of Visit,Num,21380,2020,-28,8,22,36,64,92,120,162,225,365,2085
EMD_NCT01016483_1_mek,LB,ETCD,Element Code,Char,22968,432,MONOTHER,PTP,TRT_PLA,TRT_PLA,TRT_PLA,TRT_PLA,TRT_PLA,TRT_PLA,TRT_PLA,TRT_PLA,UNPLAN
EMD_NCT01016483_1_mek,LB,ELEMENT,Description of Element,Char,22915,485,Gemcitabine and Placebo,Gemcitabine and Placebo,Gemcitabine and Placebo,Gemcitabine and Placebo,Gemcitabine and Placebo,Gemcitabine and Placebo,Gemcitabine and Placebo,Gemcitabine and Placebo,Gemcitabine and Placebo,Post Treatment Period,Screening
EMD_NCT01016483_1_mek,LB,EPOCH,Epoch,Char,22968,432,MONOTHERAPY POST TREATMENT,POST TREATMENT,TREATMENT,TREATMENT,TREATMENT,TREATMENT,TREATMENT,TREATMENT,TREATMENT,TREATMENT,TREATMENT
EMD_NCT01016483_1_mek,LB,LBDTC,Date/Time of Specimen Collection,Char,23400,0,******,2013-05-24,2013-07-16,2013-08-14,2013-09-11,2013-10-10,2013-11-13,2013-12-26,2014-02-24,2014-06-07,2015-03-16
EMD_NCT01016483_1_mek,LB,LBDY,Study Day of Specimen Collection,Num,23108,292,-487,8,22,36,64,92,120,162,218,302,646
EMD_NCT01016483_1_mek,MH,STUDYID,Study Identifier,Char,270,0,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003
EMD_NCT01016483_1_mek,MH,DOMAIN,Domain Abbreviation,Char,270,0,MH,MH,MH,MH,MH,MH,MH,MH,MH,MH,MH
EMD_NCT01016483_1_mek,MH,USUBJID,Unique Subject Identifier,Char,270,0,1,6,13,16,20,24,29,32,35,40,44
EMD_NCT01016483_1_mek,MH,MHSEQ,Sequence Number,Num,270,0,1,1,2,2,3,4,5,6,7,10,19
EMD_NCT01016483_1_mek,MH,MHSPID,Sponsor-Defined Identifier,Char,226,44,1,1,10,2,2,3,4,5,6,7,9
EMD_NCT01016483_1_mek,MH,MHTERM,Reported Term for the Medical History,Char,0,270,,,,,,,,,,,
EMD_NCT01016483_1_mek,MH,MHLLT,Lowest Level Term,Char,226,44,Abdominal pain,Aortic aneurysm repair,Cancer pain,Coronary artery disease,Escherichia sepsis,Hiatal hernia,Hypertension arterial,Myocardial infarction,Pneumonia cytomegaloviral,Thyroid nodule,White coat hypertension
EMD_NCT01016483_1_mek,MH,MHLLTCD,Lowest Level Term Code,Num,226,44,10000081,10003008,10008847,10012735,10019093,10020775,10027401,10036135,10045242,10053361,10072639
EMD_NCT01016483_1_mek,MH,MHDECOD,Dictionary-Derived Term,Char,226,44,Abdominal distension,Anaemia,Benign prostatic hyperplasia,Constipation,Diabetes mellitus,Hepatomegaly,Hypertension,Mesenteric vascular insufficiency,Pancreatitis,Thrombophlebitis,Weight decreased
EMD_NCT01016483_1_mek,MH,MHPTCD,Preferred Term Code,Num,226,44,10000060,10002034,10007027,10011078,10018304,10020772,10027401,10034636,10046274,10058108,10072562
EMD_NCT01016483_1_mek,MH,MHHLT,High Level Term,Char,226,44,Abdominal and gastrointestinal infections,Appetite disorders,Bronchospasm and obstruction,Diabetes mellitus (incl subtypes),Extremity deformities,Gastrointestinal atonic and hypomotility disorders NEC,Ischaemic coronary artery disorders,Oncologic complications and emergencies,Rate and rhythm disorders NEC,Uterine therapeutic procedures,Vascular hypertensive disorders NEC
EMD_NCT01016483_1_mek,MH,MHHLTCD,High Level Term Code,Num,226,44,10001910,10003550,10008636,10012602,10016770,10017933,10020774,10025439,10034572,10046309,10071941
EMD_NCT01016483_1_mek,MH,MHHLGT,High Level Group Term,Char,226,44,Abdominal hernias and other abdominal wall conditions,Blood and lymphatic system disorders congenital,Embolism and thrombosis,Gastrointestinal motility and defaecation conditions,Gastrointestinal signs and symptoms,Glucose metabolism disorders (incl diabetes mellitus),Infections - pathogen unspecified,Musculoskeletal and connective tissue disorders NEC,Reproductive neoplasms male malignant and unspecified,Vascular hypertensive disorders,Vitamin related disorders
EMD_NCT01016483_1_mek,MH,MHHLGTCD,High Level Group Term Code,Num,226,44,10000073,10004018,10012375,10017628,10018012,10018073,10019654,10028393,10040991,10057166,10071940
EMD_NCT01016483_1_mek,MH,MHCAT,Category for Medical History,Char,270,0,DISEASE HISTORY,DISEASE HISTORY,UNRELATED TO STUDY CONDITION,UNRELATED TO STUDY CONDITION,UNRELATED TO STUDY CONDITION,UNRELATED TO STUDY CONDITION,UNRELATED TO STUDY CONDITION,UNRELATED TO STUDY CONDITION,UNRELATED TO STUDY CONDITION,UNRELATED TO STUDY CONDITION,UNRELATED TO STUDY CONDITION
EMD_NCT01016483_1_mek,MH,MHBODSYS,Body System or Organ Class,Char,226,44,Blood and lymphatic system disorders,Eye disorders,Gastrointestinal disorders,Gastrointestinal disorders,Infections and infestations,Metabolism and nutrition disorders,Musculoskeletal and connective tissue disorders,Psychiatric disorders,Skin and subcutaneous tissue disorders,Vascular disorders,Vascular disorders
EMD_NCT01016483_1_mek,MH,MHBDSYCD,Body System or Organ Class Code,Num,226,44,10005329,10015919,10017947,10017947,10021881,10027433,10028395,10037175,10040785,10047065,10047065
EMD_NCT01016483_1_mek,MH,MHSOC,Primary System Organ Class,Char,226,44,Blood and lymphatic system disorders,Eye disorders,Gastrointestinal disorders,Gastrointestinal disorders,Infections and infestations,Metabolism and nutrition disorders,Musculoskeletal and connective tissue disorders,Psychiatric disorders,Skin and subcutaneous tissue disorders,Vascular disorders,Vascular disorders
EMD_NCT01016483_1_mek,MH,MHSOCCD,Primary System Organ Class Code,Num,226,44,10005329,10015919,10017947,10017947,10021881,10027433,10028395,10037175,10040785,10047065,10047065
EMD_NCT01016483_1_mek,MH,MHREL,Causality,Char,226,44,NOT RELATED TO STUDY CONDITION,NOT RELATED TO STUDY CONDITION,NOT RELATED TO STUDY CONDITION,NOT RELATED TO STUDY CONDITION,NOT RELATED TO STUDY CONDITION,NOT RELATED TO STUDY CONDITION,NOT RELATED TO STUDY CONDITION,NOT RELATED TO STUDY CONDITION,RELATED TO STUDY CONDITION,RELATED TO STUDY CONDITION,UNKNOWN RELATIONSHIP TO STUDY CONDITION
EMD_NCT01016483_1_mek,MH,MHTOXGR,Standard Toxicity Grade,Char,138,132,1,1,1,1,1,1,1,2,2,2,3
EMD_NCT01016483_1_mek,MH,ETCD,Element Code,Char,7,263,SCRN,,,SCRN,,SCRN,SCRN,,SCRN,SCRN,SCRN
EMD_NCT01016483_1_mek,MH,ELEMENT,Description of Element,Char,7,263,Screening,,,Screening,,Screening,Screening,,Screening,Screening,Screening
EMD_NCT01016483_1_mek,MH,EPOCH,Epoch,Char,7,263,SCREENING,,,SCREENING,,SCREENING,SCREENING,,SCREENING,SCREENING,SCREENING
EMD_NCT01016483_1_mek,MH,MHSTDTC,Start Date/Time of Medical History Event,Char,270,0,******,1984,2001,2007,2011-02,2012-08-20,2013-02-07,2013-05,2013-06,2013-06-27,2013-09-29
EMD_NCT01016483_1_mek,MH,MHENDTC,End Date/Time of Medical History Event,Char,270,0,******,******,******,******,******,******,******,******,2004,2013-02,2013-10-22
EMD_NCT01016483_1_mek,MH,MHSTDY,Study Day of Start of History Event,Num,103,167,-5354,-1288,-487,-139,-60,-49,-35,-26,-20,-12,-3
EMD_NCT01016483_1_mek,MH,MHENDY,Study Day of End of History Event,Num,23,247,-5344,-2596,-1328,-358,-105,-35,-1,1,8,20,120
EMD_NCT01016483_1_mek,MH,MHENRTPT,End Relative to Reference Time Point,Char,218,52,BEFORE,BEFORE,BEFORE,BEFORE,ONGOING,ONGOING,ONGOING,ONGOING,ONGOING,ONGOING,ONGOING
EMD_NCT01016483_1_mek,MH,MHENTPT,End Reference Time Point,Char,218,52,SCREENING,SCREENING,SCREENING,SCREENING,SCREENING,SCREENING,SCREENING,SCREENING,SCREENING,SCREENING,SCREENING
EMD_NCT01016483_1_mek,RS,STUDYID,Study Identifier,Char,425,0,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003
EMD_NCT01016483_1_mek,RS,DOMAIN,Domain Abbreviation,Char,425,0,RS,RS,RS,RS,RS,RS,RS,RS,RS,RS,RS
EMD_NCT01016483_1_mek,RS,USUBJID,Unique Subject Identifier,Char,425,0,1,5,7,8,17,21,26,34,37,41,44
EMD_NCT01016483_1_mek,RS,RSSEQ,Sequence Number,Num,425,0,1,2,3,4,6,8,11,14,18,23,44
EMD_NCT01016483_1_mek,RS,RSGRPID,Group ID,Char,425,0,CYCLE 1,CYCLE 1,CYCLE 1,CYCLE 1,CYCLE 3,CYCLE 3,CYCLE 5,CYCLE 7,CYCLE 9,MONOTHERAPY CYCLE 2,UNSCHEDULED 02
EMD_NCT01016483_1_mek,RS,RSLNKGRP,Link Group,Char,425,0,NEWCYCLE 1,NEWCYCLE 21,NEWCYCLE 9,NTCYCLE 1,NTCYCLE 5,NTUNSCHEDULED 01,OVRLCYCLE 15,OVRLCYCLE 7,TCYCLE 1,TCYCLE 5,TUNSCHEDULED 02
EMD_NCT01016483_1_mek,RS,RSTESTCD,Response Assessment Short Name,Char,425,0,NEWLES,NEWLES,NEWLES,NTRGRESP,NTRGRESP,NTRGRESP,OVRLRESP,OVRLRESP,TRGRESP,TRGRESP,TRGRESP
EMD_NCT01016483_1_mek,RS,RSTEST,Response Assessment Name,Char,425,0,New Lesion,New Lesion,New Lesion,Non-target Response,Non-target Response,Non-target Response,Overall Response,Overall Response,Target Response,Target Response,Target Response
EMD_NCT01016483_1_mek,RS,RSCAT,Category for Response Assessment,Char,425,0,RECIST 1.0,RECIST 1.0,RECIST 1.0,RECIST 1.0,RECIST 1.0,RECIST 1.0,RECIST 1.0,RECIST 1.0,RECIST 1.0,RECIST 1.0,RECIST 1.0
EMD_NCT01016483_1_mek,RS,RSORRES,Response Assessment Result,Char,425,0,COMPLETE RESPONSE,N,NON-COMPLETE RESPONSE/STABLE DISEASE,NON-COMPLETE RESPONSE/STABLE DISEASE,NOT ASSESSABLE,PROGRESSIVE DISEASE,PROGRESSIVE DISEASE,STABLE DISEASE,STABLE DISEASE,STABLE DISEASE,Y
EMD_NCT01016483_1_mek,RS,RSSTRESC,Response Assessment Result Std. Format,Char,425,0,CR,N,NON-CR/SD,NON-CR/SD,NOT ASSESSABLE,PD,PR,SD,SD,SD,Y
EMD_NCT01016483_1_mek,RS,VISITNUM,Visit Number,Num,425,0,156,156,156,156,328,328,528,728,1128,16777,99994
EMD_NCT01016483_1_mek,RS,VISIT,Visit Name,Char,425,0,CYCLE 1 DAY 56,CYCLE 1 DAY 56,CYCLE 1 DAY 56,CYCLE 1 DAY 56,CYCLE 3 DAY 1 UNSCHEDULED 1,CYCLE 3 DAY 28,CYCLE 4 DAY 22 UNSCHEDULED 1,CYCLE 5 DAY 28,CYCLE 7 DAY 28,END OF TREATMENT,STUDY TERMINATION UNSCHEDULED 1
EMD_NCT01016483_1_mek,RS,VISITDY,Planned Study Day of Visit,Num,365,60,56,56,56,56,112,112,168,224,280,392,2056
EMD_NCT01016483_1_mek,RS,ETCD,Element Code,Char,425,0,FU,PTP,TRT_PLA,TRT_PLA,TRT_PLA,TRT_PLA,TRT_PLA,TRT_PLA,TRT_PLA,TRT_PLA,TRT_PLA
EMD_NCT01016483_1_mek,RS,ELEMENT,Description of Element,Char,425,0,Follow-up Period,Gemcitabine and Placebo,Gemcitabine and Placebo,Gemcitabine and Placebo,Gemcitabine and Placebo,Gemcitabine and Placebo,Gemcitabine and Placebo,Gemcitabine and Placebo,Gemcitabine and Placebo,Post Treatment Period,Post Treatment Period
EMD_NCT01016483_1_mek,RS,EPOCH,Epoch,Char,425,0,FOLLOW-UP,POST TREATMENT,TREATMENT,TREATMENT,TREATMENT,TREATMENT,TREATMENT,TREATMENT,TREATMENT,TREATMENT,TREATMENT
EMD_NCT01016483_1_mek,RS,RSDTC,Date/Time of Response Assessment,Char,425,0,2013-02-20,2013-07-07,2013-08-27,2013-09-18,2013-10-20,2013-11-25,2013-12-18,2014-01-31,2014-03-27,2014-06-18,2015-02-09
EMD_NCT01016483_1_mek,RS,RSDY,Study Day of Response Assessment,Num,425,0,17,50,52,57,106,114,164,218,241,338,611
EMD_NCT01016483_1_mek,SC,STUDYID,Study Identifier,Char,42,0,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003
EMD_NCT01016483_1_mek,SC,DOMAIN,Domain Abbreviation,Char,42,0,SC,SC,SC,SC,SC,SC,SC,SC,SC,SC,SC
EMD_NCT01016483_1_mek,SC,USUBJID,Unique Subject Identifier,Char,42,0,1,4,8,12,16,23,27,31,35,39,44
EMD_NCT01016483_1_mek,SC,SCSEQ,Sequence Number,Num,42,0,1,1,1,1,1,1,1,1,1,1,1
EMD_NCT01016483_1_mek,SC,SCTESTCD,Subject Characteristic Short Name,Char,42,0,STAGE,STAGE,STAGE,STAGE,STAGE,STAGE,STAGE,STAGE,STAGE,STAGE,STAGE
EMD_NCT01016483_1_mek,SC,SCTEST,Subject Characteristic,Char,42,0,Stage at Initial Diagnosis,Stage at Initial Diagnosis,Stage at Initial Diagnosis,Stage at Initial Diagnosis,Stage at Initial Diagnosis,Stage at Initial Diagnosis,Stage at Initial Diagnosis,Stage at Initial Diagnosis,Stage at Initial Diagnosis,Stage at Initial Diagnosis,Stage at Initial Diagnosis
EMD_NCT01016483_1_mek,SC,SCCAT,Category for Subject Characteristic,Char,42,0,INITIAL DIAGNOSIS,INITIAL DIAGNOSIS,INITIAL DIAGNOSIS,INITIAL DIAGNOSIS,INITIAL DIAGNOSIS,INITIAL DIAGNOSIS,INITIAL DIAGNOSIS,INITIAL DIAGNOSIS,INITIAL DIAGNOSIS,INITIAL DIAGNOSIS,INITIAL DIAGNOSIS
EMD_NCT01016483_1_mek,SC,SCORRES,Result or Finding in Original Units,Char,42,0,II,IIB,III,IV,IV,IV,IV,IV,IV,IV,IV
EMD_NCT01016483_1_mek,SC,SCSTRESC,Character Result/Finding in Std Format,Char,42,0,II,IIB,III,IV,IV,IV,IV,IV,IV,IV,IV
EMD_NCT01016483_1_mek,SC,ETCD,Element Code,Char,4,38,SCRN,,,,,SCRN,,,SCRN,,SCRN
EMD_NCT01016483_1_mek,SC,ELEMENT,Description of Element,Char,4,38,Screening,,,,,Screening,,,Screening,,Screening
EMD_NCT01016483_1_mek,SC,EPOCH,Epoch,Char,4,38,SCREENING,,,,,SCREENING,,,SCREENING,,SCREENING
EMD_NCT01016483_1_mek,SC,SCDTC,Date/Time of Collection,Char,42,0,2011-11-20,2012-12-22,2013-03-07,2013-04-17,2013-05-07,2013-06-18,2013-06-23,2013-06-27,2013-07-26,2013-08-17,2013-09-29
EMD_NCT01016483_1_mek,SC,SCDY,Study Day of Examination,Num,40,2,-487,-118,-69,-59,-36,-35,-27,-21,-13,-7,-3
EMD_NCT01016483_1_mek,SE,STUDYID,Study Identifier,Char,195,0,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003
EMD_NCT01016483_1_mek,SE,DOMAIN,Domain Abbreviation,Char,195,0,SE,SE,SE,SE,SE,SE,SE,SE,SE,SE,SE
EMD_NCT01016483_1_mek,SE,USUBJID,Unique Subject Identifier,Char,195,0,1,6,11,15,19,23,27,32,37,41,44
EMD_NCT01016483_1_mek,SE,SESEQ,Sequence Number,Num,195,0,1,1,1,2,2,3,3,4,4,5,7
EMD_NCT01016483_1_mek,SE,ETCD,Element Code,Char,195,0,FU,FU,MONOTHER,MSCRN,PTP,PTP,SCRN,SCRN,TRT_PLA,TRT_PLA,UNPLAN
EMD_NCT01016483_1_mek,SE,ELEMENT,Description of Element,Char,194,1,Follow-up Period,Follow-up Period,Gemcitabine and Placebo,Gemcitabine and Placebo,Gemcitabine and Placebo,Monotherapy Screening,Post Treatment Period,Post Treatment Period,Screening,Screening,Screening
EMD_NCT01016483_1_mek,SE,SESTDTC,Start Date/Time of Element,Char,195,0,2012-12-20,2013-05-06,2013-06-21,2013-07-11,2013-08-06,2013-09-04,2013-10-08,2013-10-30,2014-01-08,2014-03-12,2015-03-16
EMD_NCT01016483_1_mek,SE,SEENDTC,End Date/Time of Element,Char,195,0,******,2013-05-20,2013-07-13,2013-08-15,2013-09-26,2013-10-23,2013-11-19,2014-01-12,2014-03-12,2014-06-11,2015-03-16
EMD_NCT01016483_1_mek,SE,SESTDY,Study Day of Start of Element,Num,194,1,-33,-13,-6,1,1,29,70,110,160,239,646
EMD_NCT01016483_1_mek,SE,SEENDY,Study Day of End of Element,Num,192,3,1,1,1,29,56,86,128,177,239,330,646
EMD_NCT01016483_1_mek,SE,TAETORD,Planned Order of Elements within Arm,Num,194,1,1,1,1,2,2,3,3,4,6,7,7
EMD_NCT01016483_1_mek,SE,EPOCH,Epoch,Char,195,0,FOLLOW-UP,FOLLOW-UP,MONOTHERAPY POST TREATMENT,MONOTHERAPY TREATMENT,POST TREATMENT,POST TREATMENT,SCREENING,SCREENING,TREATMENT,TREATMENT,TREATMENT
EMD_NCT01016483_1_mek,SE,SEUPDES,Description of Unplanned Element,Char,1,194,SUBJECT TOOK SOME PIMASERTIB AND SOME PLACEBO DOSES DURING CYCLE 2,,,,,,,,,,
EMD_NCT01016483_1_mek,SUPPAE,STUDYID,Study Identifier,Char,3259,0,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003
EMD_NCT01016483_1_mek,SUPPAE,RDOMAIN,Related Domain Abbreviation,Char,3259,0,AE,AE,AE,AE,AE,AE,AE,AE,AE,AE,AE
EMD_NCT01016483_1_mek,SUPPAE,USUBJID,Unique Subject Identifier,Char,3259,0,1,5,8,17,21,21,27,32,37,39,44
EMD_NCT01016483_1_mek,SUPPAE,IDVAR,Identifying Variable,Char,3259,0,AESEQ,AESEQ,AESEQ,AESEQ,AESEQ,AESEQ,AESEQ,AESEQ,AESEQ,AESEQ,AESEQ
EMD_NCT01016483_1_mek,SUPPAE,IDVARVAL,Identifying Variable Value,Char,3259,0,1,107,13,16,2,27,34,45,6,8,99
EMD_NCT01016483_1_mek,SUPPAE,QNAM,Qualifier Variable Name,Char,3259,0,ACNCON1,ACNGEM1,ACNGEM1,ACNGEM4,AECHANGE,AESPINT,AESPINT,AESPINT,RELGEM,RELGEM,RELGEM
EMD_NCT01016483_1_mek,SUPPAE,QLABEL,Qualifier Variable Label,Char,3259,0,Action Taken with Gem 1,Action Taken with Gem 1,Action Taken with Gem 1,Adverse Event of Special Interest,Adverse Event of Special Interest,Adverse Event of Special Interest,Other Action Taken Con1,Outcome of AE: Change in Toxicity Grade,Relationship to Gemcitabine,Relationship to Gemcitabine,Relationship to Non-Study Trt 7
EMD_NCT01016483_1_mek,SUPPAE,QVAL,Data Value,Char,3259,0,?ALLERGIC TO CT/MUGA CONTRAST,CONCOMITANT MEDICATION,DOSE NOT CHANGED,DOSE NOT CHANGED,N,N,N,NOT APPLICABLE,RELATED,UNRELATED,Y
EMD_NCT01016483_1_mek,SUPPAE,QORIG,Origin,Char,3259,0,CRF,CRF,CRF,CRF,CRF,CRF,CRF,CRF,CRF,CRF,CRF
EMD_NCT01016483_1_mek,SUPPAE,QEVAL,Evaluator,Char,0,3259,,,,,,,,,,,
EMD_NCT01016483_1_mek,SUPPCM,STUDYID,Study Identifier,Char,8760,0,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003
EMD_NCT01016483_1_mek,SUPPCM,RDOMAIN,Related Domain Abbreviation,Char,8760,0,CM,CM,CM,CM,CM,CM,CM,CM,CM,CM,CM
EMD_NCT01016483_1_mek,SUPPCM,USUBJID,Unique Subject Identifier,Char,8760,0,1,3,11,17,21,25,31,34,38,41,44
EMD_NCT01016483_1_mek,SUPPCM,IDVAR,Identifying Variable,Char,8760,0,CMSEQ,CMSEQ,CMSEQ,CMSEQ,CMSEQ,CMSEQ,CMSEQ,CMSEQ,CMSEQ,CMSEQ,CMSEQ
EMD_NCT01016483_1_mek,SUPPCM,IDVARVAL,Identifying Variable Value,Char,8760,0,1,11,13,17,2,24,3,4,5,7,9
EMD_NCT01016483_1_mek,SUPPCM,QNAM,Qualifier Variable Name,Char,8760,0,ATC1C,ATC1C,ATC1T,ATC2C,ATC2T,ATC3C,ATC3T,ATC4C,ATC4T,CMINDDRC,TYPEKIN
EMD_NCT01016483_1_mek,SUPPCM,QLABEL,Qualifier Variable Label,Char,8760,0,ATC1 Code,ATC1 Code,ATC1 Text,ATC2 Code,ATC2 Text,ATC3 Code,ATC3 Text,ATC4 Code,ATC4 Text,Reason Adverse Event,Surgery Outcome Other
EMD_NCT01016483_1_mek,SUPPCM,QVAL,Data Value,Char,8760,0,%,A04,ADVERSE EVENT,ANILIDES,B,CALCIUM CHANNEL BLOCKERS,GR/10ML,MEDICAL HISTORY,NERVOUS SYSTEM,PROPULSIVES,Y
EMD_NCT01016483_1_mek,SUPPCM,QORIG,Origin,Char,8760,0,CRF,CRF,CRF,CRF,CRF,CRF,CRF,CRF,CRF,CRF,CRF
EMD_NCT01016483_1_mek,SUPPCM,QEVAL,Evaluator,Char,0,8760,,,,,,,,,,,
EMD_NCT01016483_1_mek,SUPPDS,STUDYID,Study Identifier,Char,246,0,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003
EMD_NCT01016483_1_mek,SUPPDS,RDOMAIN,Related Domain Abbreviation,Char,246,0,DS,DS,DS,DS,DS,DS,DS,DS,DS,DS,DS
EMD_NCT01016483_1_mek,SUPPDS,USUBJID,Unique Subject Identifier,Char,246,0,1,5,10,14,18,24,28,33,37,41,44
EMD_NCT01016483_1_mek,SUPPDS,IDVAR,Identifying Variable,Char,246,0,DSSEQ,DSSEQ,DSSEQ,DSSEQ,DSSEQ,DSSEQ,DSSEQ,DSSEQ,DSSEQ,DSSEQ,DSSEQ
EMD_NCT01016483_1_mek,SUPPDS,IDVARVAL,Identifying Variable Value,Char,246,0,1,1,10,3,3,3,3,5,6,6,9
EMD_NCT01016483_1_mek,SUPPDS,QNAM,Qualifier Variable Name,Char,246,0,AUTOPFL,AUTOPFL,IVRANDDT,IVRANDDT,IVRANDNO,IVRANDNO,TTPROGCD,TTPROGDT,TTPROGDT,TTTXGMDT,TTTXGMDT
EMD_NCT01016483_1_mek,SUPPDS,QLABEL,Qualifier Variable Label,Char,246,0,Autopsy Performed,Autopsy Performed,Date of Disease Progression,Date of Disease Progression,Disease Progression Determined By,Last Gemcitabine Administration Date,Last Gemcitabine Administration Date,Randomization Date/Time,Randomization Date/Time,Randomization Number,Randomization Number
EMD_NCT01016483_1_mek,SUPPDS,QVAL,Data Value,Char,246,0,02002,06015,2013-01-24,2013-05-16T10:21,2013-06-28T13:55,2013-08-08,2013-11-06,CLINICAL ASSESSMENT,N,RADIOLOGIC ASSESSMENT,Y
EMD_NCT01016483_1_mek,SUPPDS,QORIG,Origin,Char,246,0,CRF,CRF,CRF,CRF,CRF,CRF,CRF,IRT IVRS,IRT IVRS,IRT IVRS,IRT IVRS
EMD_NCT01016483_1_mek,SUPPDS,QEVAL,Evaluator,Char,0,246,,,,,,,,,,,
EMD_NCT01016483_1_mek,SUPPDV,STUDYID,Study Identifier,Char,52,0,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003
EMD_NCT01016483_1_mek,SUPPDV,RDOMAIN,Related Domain Abbreviation,Char,52,0,DV,DV,DV,DV,DV,DV,DV,DV,DV,DV,DV
EMD_NCT01016483_1_mek,SUPPDV,USUBJID,Unique Subject Identifier,Char,52,0,6,23,31,31,39,39,39,41,44,44,44
EMD_NCT01016483_1_mek,SUPPDV,IDVAR,Identifying Variable,Char,52,0,DVSEQ,DVSEQ,DVSEQ,DVSEQ,DVSEQ,DVSEQ,DVSEQ,DVSEQ,DVSEQ,DVSEQ,DVSEQ
EMD_NCT01016483_1_mek,SUPPDV,IDVARVAL,Identifying Variable Value,Char,52,0,1,16,34,34,34,4,41,5,6,65,7
EMD_NCT01016483_1_mek,SUPPDV,QNAM,Qualifier Variable Name,Char,52,0,DVTERM1,DVTERM1,DVTERM1,DVTERM1,DVTERM1,DVTERM14,DVTERM2,DVTERM2,DVTERM3,DVTERM4,DVTERM9
EMD_NCT01016483_1_mek,SUPPDV,QLABEL,Qualifier Variable Label,Char,52,0,Protocol Deviation Term,Protocol Deviation Term,Protocol Deviation Term,Protocol Deviation Term,Protocol Deviation Term,Protocol Deviation Term,Protocol Deviation Term,Protocol Deviation Term,Protocol Deviation Term,Protocol Deviation Term,Protocol Deviation Term
EMD_NCT01016483_1_mek,SUPPDV,QVAL,Data Value,Char,52,0,- EVENING DOSE AT 18:00 - 17-FEB-2013: MORNING DOSE AT 06:00 - EVENING DOSE AT 18:00 - 18-FEB-2013: MORNING DOSE AT 06:10 - EVENING DOSE AT 18:00 - 19-FEB-2013: MORNING DOSE AT 06:00 - EVENING DOSE,06:50 - EVENING DOSE AT 19:00 - 03-MAR-2013: MORNING DOSE AT 07:00 - EVENING DOSE AT 19:00 - 04-MAR-2013: MORNING DOSE AT 06:50 - EVENING DOSE AT 19:00 - 05-MAR-2013: MORNING DOSE AT 06:50 - EVENING,10-MAR-2013: MORNING DOSE AT 07:00 - EVENING DOSE AT 19:00 - 11-MAR-2013: MORNING DOSE AT 06:30 - EVENING DOSE AT 19:00 - 12-MAR-2013: MORNING DOSE AT 07:00 - EVENING DOSE AT 19:00 - 14-MAR-2013:,"21244, 21245 AND 21148. THE PATIENT TOOK 16 CAPSULES AND RETURNED 4. KIT NUMBER 21248 HAS NOT BEEN DISPENSED TO ANY PATIENT BUT IS STILL AT THE PHARMACY. THE ISSUE HAS BEEN DOCUMENTED IN A FILE NOTE",AND EVENING DOSE AT 20:00 04-JAN-2014: MORNING DOSE AT 09:00 AND EVENING DOSE AT 22:00 06-JAN-2014: MORNING DOSE AT 07:15 AND EVENING DOSE AT 20:30 09-JAN-2014: MORNING DOSE AT 09:30 AND EVENING DOSE,CAPSULES,DOSE AT 20:30 - 22-NOV-2013: MORNING DOSE AT 06:00 AND EVENING DOSE AT 23:00 - 23-NOV-2013: MORNING DOSE AT 09:30 AND EVENING DOSE AT 23:00,"HAVE BEEN 1700MG NOT 1800MG ADMINISTERED TO THE PATIENT. THIS ISSUE WAS RAISED WITH IAN PAMPHLETT, WHO SAID THAT HE WILL SPEAK WITH THE LEAD PHARMACIST TO CONFIRM AS IT COULD BE THAT THE SITE WAS",MORNING DOSE AT 07:10 - EVENING DOSE AT 19:30 - 28-FEB-2013: MORNING DOSE AT 06:30 - EVENING DOSE AT 19:30 - 01-MAR-2013: MORNING DOSE AT 06:30 - EVENING DOSE AT 19:00 - 02-MAR-2013: MORNING DOSE AT,SIGNED BY THE PHARMACIST AND BY THE PRINCIPAL INVESTIGATOR. CRA RE-TRAINED THE PHARMACIST AND A SITE STAFF TRAINING LOG HAS BEEN COMPLETED,WILL BE ASKED TO DESTROY THE SAMPLE.
EMD_NCT01016483_1_mek,SUPPDV,QORIG,Origin,Char,52,0,EXTERNAL,EXTERNAL,EXTERNAL,EXTERNAL,EXTERNAL,EXTERNAL,EXTERNAL,EXTERNAL,EXTERNAL,EXTERNAL,EXTERNAL
EMD_NCT01016483_1_mek,SUPPDV,QEVAL,Evaluator,Char,0,52,,,,,,,,,,,
EMD_NCT01016483_1_mek,SUPPEG,STUDYID,Study Identifier,Char,1163,0,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003
EMD_NCT01016483_1_mek,SUPPEG,RDOMAIN,Related Domain Abbreviation,Char,1163,0,EG,EG,EG,EG,EG,EG,EG,EG,EG,EG,EG
EMD_NCT01016483_1_mek,SUPPEG,USUBJID,Unique Subject Identifier,Char,1163,0,1,5,9,14,21,24,27,34,37,41,44
EMD_NCT01016483_1_mek,SUPPEG,IDVAR,Identifying Variable,Char,1163,0,EGGRPID,EGGRPID,EGGRPID,EGGRPID,EGGRPID,EGGRPID,EGGRPID,EGGRPID,EGGRPID,EGGRPID,EGGRPID
EMD_NCT01016483_1_mek,SUPPEG,IDVARVAL,Identifying Variable Value,Char,1163,0,CYCLE 1 DAY 1 2012-11-26 1 HOUR POST DOSE ECG,CYCLE 1 DAY 1 2013-07-01 1 HOUR POST DOSE ECG,CYCLE 1 DAY 15 2013-07-18 1 HOUR POST DOSE ECG,CYCLE 1 DAY 22 2013-02-14 1 HOUR POST DOSE ECG,CYCLE 1 DAY 29 2013-04-11 PRE-DOSE ECG,CYCLE 1 DAY 36 2013-07-11 1 HOUR POST DOSE ECG,CYCLE 1 DAY 8 2013-01-31 4 HOURS POST DOSE ECG,CYCLE 12 DAY 1 2014-04-17 PRE-DOSE ECG,CYCLE 4 DAY 1 2013-06-13 PRE-DOSE ECG,MONOTHERAPY CYCLE 1 DAY 1 2013-03-29 PRE-DOSE ECG,UNSCHEDULED 2014-03-18 ECG
EMD_NCT01016483_1_mek,SUPPEG,QNAM,Qualifier Variable Name,Char,1163,0,PRECG,PRECG,PRECG,PRECG,PRECG,PRECG,PRECG,PRECG,PRECG,PRECG,PRECG
EMD_NCT01016483_1_mek,SUPPEG,QLABEL,Qualifier Variable Label,Char,1163,0,Comparison of Previous ECGs,Comparison of Previous ECGs,Comparison of Previous ECGs,Comparison of Previous ECGs,Comparison of Previous ECGs,Comparison of Previous ECGs,Comparison of Previous ECGs,Comparison of Previous ECGs,Comparison of Previous ECGs,Comparison of Previous ECGs,Comparison of Previous ECGs
EMD_NCT01016483_1_mek,SUPPEG,QVAL,Data Value,Char,1163,0,COMPARISON NOT AVAILABLE,DETERIORATED,IMPROVED,NO CHANGE,NO CHANGE,NO CHANGE,NO CHANGE,NO CHANGE,NO CHANGE,NO CHANGE,NO CHANGE
EMD_NCT01016483_1_mek,SUPPEG,QORIG,Origin,Char,1163,0,EXTERNAL,EXTERNAL,EXTERNAL,EXTERNAL,EXTERNAL,EXTERNAL,EXTERNAL,EXTERNAL,EXTERNAL,EXTERNAL,EXTERNAL
EMD_NCT01016483_1_mek,SUPPEG,QEVAL,Evaluator,Char,0,1163,,,,,,,,,,,
EMD_NCT01016483_1_mek,SUPPEX,STUDYID,Study Identifier,Char,10979,0,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003
EMD_NCT01016483_1_mek,SUPPEX,RDOMAIN,Related Domain Abbreviation,Char,10979,0,EX,EX,EX,EX,EX,EX,EX,EX,EX,EX,EX
EMD_NCT01016483_1_mek,SUPPEX,USUBJID,Unique Subject Identifier,Char,10979,0,1,5,5,8,17,21,26,33,37,40,44
EMD_NCT01016483_1_mek,SUPPEX,IDVAR,Identifying Variable,Char,10979,0,EXGRPID,EXSEQ,EXSEQ,EXSEQ,EXSEQ,EXSEQ,EXSEQ,EXSEQ,EXSEQ,EXSEQ,EXSEQ
EMD_NCT01016483_1_mek,SUPPEX,IDVARVAL,Identifying Variable Value,Char,10979,0,10,127,17,216,270,34,425,516,656,84,PLACEBO CYCLE 9
EMD_NCT01016483_1_mek,SUPPEX,QNAM,Qualifier Variable Name,Char,10979,0,ADJAE,RTDDPLAC,RTDDPLAC,RTDDPLAC,RTDDPLAC,RTDDPLAC,RTDDPLAC,RTDDPLAC,RTDDPLAC,RTDDPLAC,RTDDPLAC
EMD_NCT01016483_1_mek,SUPPEX,QLABEL,Qualifier Variable Label,Char,10979,0,Cycle Visit Number,Recorded Total Daily Dose for Placebo,Recorded Total Daily Dose for Placebo,Recorded Total Daily Dose for Placebo,Recorded Total Daily Dose for Placebo,Recorded Total Daily Dose for Placebo,Recorded Total Daily Dose for Placebo,Recorded Total Daily Dose for Placebo,Recorded Total Daily Dose for Placebo,Recorded Total Daily Dose for Placebo,Recorded Total Daily Dose for Placebo
EMD_NCT01016483_1_mek,SUPPEX,QVAL,Data Value,Char,10979,0,0,120,120,120,120,120,120,120,120,6,Y
EMD_NCT01016483_1_mek,SUPPEX,QORIG,Origin,Char,10979,0,CRF,CRF,CRF,CRF,CRF,CRF,CRF,CRF,CRF,CRF,CRF
EMD_NCT01016483_1_mek,SUPPEX,QEVAL,Evaluator,Char,0,10979,,,,,,,,,,,
EMD_NCT01016483_1_mek,SUPPLB,STUDYID,Study Identifier,Char,55,0,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003
EMD_NCT01016483_1_mek,SUPPLB,RDOMAIN,Related Domain Abbreviation,Char,55,0,LB,LB,LB,LB,LB,LB,LB,LB,LB,LB,LB
EMD_NCT01016483_1_mek,SUPPLB,USUBJID,Unique Subject Identifier,Char,55,0,8,8,11,16,20,22,31,38,40,41,44
EMD_NCT01016483_1_mek,SUPPLB,IDVAR,Identifying Variable,Char,55,0,LBSEQ,LBSEQ,LBSEQ,LBSEQ,LBSEQ,LBSEQ,LBSEQ,LBSEQ,LBSEQ,LBSEQ,LBSEQ
EMD_NCT01016483_1_mek,SUPPLB,IDVARVAL,Identifying Variable Value,Char,55,0,1011,135,167,197,243,30,35,36,422,632,825
EMD_NCT01016483_1_mek,SUPPLB,QNAM,Qualifier Variable Name,Char,55,0,LBORNRU,LBORNRU,LBORNRU,LBORNRU,LBORNRU,LBORNRU,LBORNRU,LBORNRU,LBORNRU,LBORNRU,LBREAOTH
EMD_NCT01016483_1_mek,SUPPLB,QLABEL,Qualifier Variable Label,Char,55,0,Reason Pregnancy Test Not Done Other,Reference Range Original Units,Reference Range Original Units,Reference Range Original Units,Reference Range Original Units,Reference Range Original Units,Reference Range Original Units,Reference Range Original Units,Reference Range Original Units,Reference Range Original Units,Reference Range Original Units
EMD_NCT01016483_1_mek,SUPPLB,QVAL,Data Value,Char,55,0,KU/L,KU/L,KU/L,kU/L,kU/L,kU/L,kU/L,kU/L,kU/L,kint.u./L,kint.u./L
EMD_NCT01016483_1_mek,SUPPLB,QORIG,Origin,Char,55,0,CRF,SITE,SITE,SITE,SITE,SITE,SITE,SITE,SITE,SITE,SITE
EMD_NCT01016483_1_mek,SUPPLB,QEVAL,Evaluator,Char,0,55,,,,,,,,,,,
EMD_NCT01016483_1_mek,SUPPMH,STUDYID,Study Identifier,Char,92,0,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003
EMD_NCT01016483_1_mek,SUPPMH,RDOMAIN,Related Domain Abbreviation,Char,92,0,MH,MH,MH,MH,MH,MH,MH,MH,MH,MH,MH
EMD_NCT01016483_1_mek,SUPPMH,USUBJID,Unique Subject Identifier,Char,92,0,1,5,9,13,17,22,27,31,36,40,44
EMD_NCT01016483_1_mek,SUPPMH,IDVAR,Identifying Variable,Char,92,0,MHSEQ,MHSEQ,MHSEQ,MHSEQ,MHSEQ,MHSEQ,MHSEQ,MHSEQ,MHSEQ,MHSEQ,MHSEQ
EMD_NCT01016483_1_mek,SUPPMH,IDVARVAL,Identifying Variable Value,Char,92,0,1,1,1,1,1,1,1,1,1,1,1
EMD_NCT01016483_1_mek,SUPPMH,QNAM,Qualifier Variable Name,Char,92,0,HISTOTH,HISTTYPE,HISTTYPE,HISTTYPE,HISTTYPE,HISTTYPE,TPDTC,TPDTC,TPDTC,TPDTC,TPDTC
EMD_NCT01016483_1_mek,SUPPMH,QLABEL,Qualifier Variable Label,Char,92,0,First Occurrence Date,First Occurrence Date,First Occurrence Date,First Occurrence Date,First Occurrence Date,Other Histocytologic Type,Tumor Histopathologic or Cytologic Type,Tumor Histopathologic or Cytologic Type,Tumor Histopathologic or Cytologic Type,Tumor Histopathologic or Cytologic Type,Tumor Histopathologic or Cytologic Type
EMD_NCT01016483_1_mek,SUPPMH,QVAL,Data Value,Char,92,0,2012-10-26,2013-01-22,2013-04-10,2013-05-13,2013-06-02,ADENOCARCINOMA OF PANCREAS,ADENOCARCINOMA OF PANCREAS,ADENOCARCINOMA OF PANCREAS,ADENOCARCINOMA OF PANCREAS,ADENOCARCINOMA OF PANCREAS,OTHER
EMD_NCT01016483_1_mek,SUPPMH,QORIG,Origin,Char,92,0,CRF,CRF,CRF,CRF,CRF,CRF,CRF,CRF,CRF,CRF,CRF
EMD_NCT01016483_1_mek,SUPPMH,QEVAL,Evaluator,Char,0,92,,,,,,,,,,,
EMD_NCT01016483_1_mek,SUPPRS,STUDYID,Study Identifier,Char,1,0,0200066003,,,,,,,,,,
EMD_NCT01016483_1_mek,SUPPRS,RDOMAIN,Related Domain Abbreviation,Char,1,0,RS,,,,,,,,,,
EMD_NCT01016483_1_mek,SUPPRS,USUBJID,Unique Subject Identifier,Char,1,0,16,,,,,,,,,,
EMD_NCT01016483_1_mek,SUPPRS,IDVAR,Identifying Variable,Char,1,0,RSSEQ,,,,,,,,,,
EMD_NCT01016483_1_mek,SUPPRS,IDVARVAL,Identifying Variable Value,Char,1,0,3,,,,,,,,,,
EMD_NCT01016483_1_mek,SUPPRS,QNAM,Qualifier Variable Name,Char,1,0,OVRNACOM,,,,,,,,,,
EMD_NCT01016483_1_mek,SUPPRS,QLABEL,Qualifier Variable Label,Char,1,0,Overall Response NA Comment,,,,,,,,,,
EMD_NCT01016483_1_mek,SUPPRS,QVAL,Data Value,Char,1,0,TARGETED LIVER LESIONS 2 AND 3 NOT MEASURABLE ANYMORE DUE TO VASCULARISATION TROUBLE,,,,,,,,,,
EMD_NCT01016483_1_mek,SUPPRS,QORIG,Origin,Char,1,0,CRF,,,,,,,,,,
EMD_NCT01016483_1_mek,SUPPRS,QEVAL,Evaluator,Char,0,1,,,,,,,,,,,
EMD_NCT01016483_1_mek,SUPPXX,STUDYID,Study Identifier,Char,9037,0,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003
EMD_NCT01016483_1_mek,SUPPXX,RDOMAIN,Related Domain Abbreviation,Char,9037,0,XX,XX,XX,XX,XX,XX,XX,XX,XX,XX,XX
EMD_NCT01016483_1_mek,SUPPXX,USUBJID,Unique Subject Identifier,Char,9037,0,1,5,6,9,17,21,26,34,37,41,44
EMD_NCT01016483_1_mek,SUPPXX,IDVAR,Identifying Variable,Char,9037,0,XXSEQ,XXSEQ,XXSEQ,XXSEQ,XXSEQ,XXSEQ,XXSEQ,XXSEQ,XXSEQ,XXSEQ,XXSEQ
EMD_NCT01016483_1_mek,SUPPXX,IDVARVAL,Identifying Variable Value,Char,9037,0,1,115,15,2,25,30,39,48,6,73,99
EMD_NCT01016483_1_mek,SUPPXX,QNAM,Qualifier Variable Name,Char,9037,0,IVASGNDT,IVASGNDT,IVCYCLE,IVKITNO,IVKITNO,IVKITSBJ,IVKITYPD,IVKITYPD,IVKITYPE,IVTRTCD,IVTRTCD
EMD_NCT01016483_1_mek,SUPPXX,QLABEL,Qualifier Variable Label,Char,9037,0,Assign Date/Time,Assign Date/Time,Cycle,Kit Number,Kit Number,Kit Type,Kit Type Decode,Kit Type Decode,Subject Number Kit Was Assigned To,Treatment Arm Code,Treatment Arm Code
EMD_NCT01016483_1_mek,SUPPXX,QVAL,Data Value,Char,9037,0,1,1920002,2013-09-05T08:23,20932,2920003,8030001,A,A,Pimasertib 30 mg matching placebo,T,X
EMD_NCT01016483_1_mek,SUPPXX,QORIG,Origin,Char,9037,0,IRT IVRS,IRT IVRS,IRT IVRS,IRT IVRS,IRT IVRS,IRT IVRS,IRT IVRS,IRT IVRS,IRT IVRS,IRT IVRS,IRT IVRS
EMD_NCT01016483_1_mek,SUPPXX,QEVAL,Evaluator,Char,0,9037,,,,,,,,,,,
EMD_NCT01016483_1_mek,SUPPYF,STUDYID,Study Identifier,Char,29,0,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003
EMD_NCT01016483_1_mek,SUPPYF,RDOMAIN,Related Domain Abbreviation,Char,29,0,YF,YF,YF,YF,YF,YF,YF,YF,YF,YF,YF
EMD_NCT01016483_1_mek,SUPPYF,USUBJID,Unique Subject Identifier,Char,29,0,3,6,14,14,16,18,20,23,34,41,41
EMD_NCT01016483_1_mek,SUPPYF,IDVAR,Identifying Variable,Char,29,0,YFSEQ,YFSEQ,YFSEQ,YFSEQ,YFSEQ,YFSEQ,YFSEQ,YFSEQ,YFSEQ,YFSEQ,YFSEQ
EMD_NCT01016483_1_mek,SUPPYF,IDVARVAL,Identifying Variable Value,Char,29,0,1,1,1,1,11,15,3,4,5,6,9
EMD_NCT01016483_1_mek,SUPPYF,QNAM,Qualifier Variable Name,Char,29,0,YFCLSP,YFCLSP,YFCLSP,YFIMSP,YFIMSP,YFIMSP,YFIMSP,YFIMSP,YFIMSP,YFIMSP,YFIMSP
EMD_NCT01016483_1_mek,SUPPYF,QLABEL,Qualifier Variable Label,Char,29,0,Specification of Clinical Confirmation,Specification of Clinical Confirmation,Specification of Clinical Confirmation,Specification of Imaging,Specification of Imaging,Specification of Imaging,Specification of Imaging,Specification of Imaging,Specification of Imaging,Specification of Imaging,Specification of Imaging
EMD_NCT01016483_1_mek,SUPPYF,QVAL,Data Value,Char,29,0,12/11/13 AT CYCLE 3 CT SCAN,"BILATERAL PLEURAL EFFUSION WITH HYDRO PNEUMOTHORAX, PANCREATIC TUMEUR  AND LIVER METASTASIS INCREASE WITH ASCITES  CONFIRMED BY CT SCAN",CT DCAN CONFIRMED PROGRESSION 29/01/2014,CT SCAN 29/1/14,CT SCAN ON 29/1/14,CT-SCAN WITH CONTRAST,INCREASE OF LIVER METASTASIS AND ASCITE CONFIRMED BY CT SAN,LIVER METASTASIS INCREASE,SEVERE WORSENING OF GENERAL STATUS,TAC,WORSENNING CLINICAL CONDITIONS AND SUSPECTED DISEASE PROGRESSION.
EMD_NCT01016483_1_mek,SUPPYF,QORIG,Origin,Char,29,0,CRF,CRF,CRF,CRF,CRF,CRF,CRF,CRF,CRF,CRF,CRF
EMD_NCT01016483_1_mek,SUPPYF,QEVAL,Evaluator,Char,0,29,,,,,,,,,,,
EMD_NCT01016483_1_mek,SUPPZO,STUDYID,Study Identifier,Char,518,0,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003
EMD_NCT01016483_1_mek,SUPPZO,RDOMAIN,Related Domain Abbreviation,Char,518,0,ZO,ZO,ZO,ZO,ZO,ZO,ZO,ZO,ZO,ZO,ZO
EMD_NCT01016483_1_mek,SUPPZO,USUBJID,Unique Subject Identifier,Char,518,0,1,5,8,13,20,25,27,34,37,41,44
EMD_NCT01016483_1_mek,SUPPZO,IDVAR,Identifying Variable,Char,518,0,ZOSEQ,ZOSEQ,ZOSEQ,ZOSEQ,ZOSEQ,ZOSEQ,ZOSEQ,ZOSEQ,ZOSEQ,ZOSEQ,ZOSEQ
EMD_NCT01016483_1_mek,SUPPZO,IDVARVAL,Identifying Variable Value,Char,518,0,100,130,169,223,26,29,310,56,62,84,99
EMD_NCT01016483_1_mek,SUPPZO,QNAM,Qualifier Variable Name,Char,518,0,ABNOTH1,ABNOTH1,OPVFTHXT,VISACCOR,VISACCOR,VISACCOR,VISACCOR,VISACCOR,VISACCOR,VISACCOR,VISACCOR
EMD_NCT01016483_1_mek,SUPPZO,QLABEL,Qualifier Variable Label,Char,518,0,Corrected Visual Acuity,Corrected Visual Acuity,Corrected Visual Acuity,Corrected Visual Acuity,Corrected Visual Acuity,Corrected Visual Acuity,Corrected Visual Acuity,Corrected Visual Acuity,Other Abnormalities,Other Technique Used,Serous Retinal Detachment
EMD_NCT01016483_1_mek,SUPPZO,QVAL,Data Value,Char,518,0,0.2,10,10,5,8,BILATERAL EARLY CATARACTE,CORRECTED VALUE UNAVAILABLE,CORRECTED VALUE UNAVAILABLE,DEVIATION EXTR. 5 DEGREE,NOT DONE,UNKNOWN
EMD_NCT01016483_1_mek,SUPPZO,QORIG,Origin,Char,518,0,CRF,CRF,CRF,CRF,CRF,CRF,CRF,CRF,CRF,CRF,CRF
EMD_NCT01016483_1_mek,SUPPZO,QEVAL,Evaluator,Char,0,518,,,,,,,,,,,
EMD_NCT01016483_1_mek,SV,STUDYID,Study Identifier,Char,1492,0,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003
EMD_NCT01016483_1_mek,SV,DOMAIN,Domain Abbreviation,Char,1492,0,SV,SV,SV,SV,SV,SV,SV,SV,SV,SV,SV
EMD_NCT01016483_1_mek,SV,USUBJID,Unique Subject Identifier,Char,1492,0,1,5,8,11,18,22,26,33,37,41,44
EMD_NCT01016483_1_mek,SV,VISITNUM,Visit Number,Num,1492,0,1,108,129,150,222,401,608,1022,16777,20101,99995
EMD_NCT01016483_1_mek,SV,VISIT,Visit Name,Char,1492,0,CYCLE 1 DAY 1,CYCLE 1 DAY 22,CYCLE 1 DAY 43,CYCLE 1 DAY 8,CYCLE 2 DAY 15,CYCLE 3 DAY 22,CYCLE 5 DAY 22,CYCLE 8 DAY 22,MONOTHERAPY CYCLE 1 DAY 15,POST TREATMENT PERIOD,TREATMENT TERMINATION UNSCHEDULED 3
EMD_NCT01016483_1_mek,SV,VISITDY,Planned Study Day of Visit,Num,1138,354,-28,2,22,36,50,71,112,162,225,414,2127
EMD_NCT01016483_1_mek,SV,SVSTDTC,Start Date/Time of Visit,Char,1492,0,******,******,2013-05-28,2013-07-20,2013-08-24,2013-09-24,2013-10-28,2013-12-09,2014-02-03,2014-05-12,2015-03-16
EMD_NCT01016483_1_mek,SV,SVENDTC,End Date/Time of Visit,Char,1492,0,******,******,2013-05-28,2013-07-20,2013-08-24,2013-09-25,2013-10-29,2013-12-10,2014-02-05,2014-05-14,2015-03-16
EMD_NCT01016483_1_mek,SV,SVSTDY,Study Day of Start of Visit,Num,1310,182,-29,2,22,44,59,92,120,162,218,296,646
EMD_NCT01016483_1_mek,SV,SVENDY,Study Day of End of Visit,Num,1310,182,-29,2,22,44,59,92,120,162,219,302,646
EMD_NCT01016483_1_mek,SV,SVUPDES,Description of Unplanned Visit,Char,113,1379,"BLOOD CHEMISTRY, CREATINE KINASE","BLOOD CHEMISTRY, HAEMATOLOGY, CREATINE KINASE","BLOOD CHEMISTRY, HAEMATOLOGY, CREATINE KINASE",CREATINE KINASE,CREATINE KINASE,ELECTROCARDIOGRAM,ELECTROCARDIOGRAM,"HAEMATOLOGY, CREATINE KINASE",OPHTHALMOLOGICAL EXAMINATION,PHARMACOKINETIC MSC1936369B BLOOD SAMPLE,"VITAL SIGNS, BLOOD CHEMISTRY, HAEMATOLOGY, CREATINE KINASE"
EMD_NCT01016483_1_mek,TA,STUDYID,Study Identifier,Char,11,0,0200066003,,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003
EMD_NCT01016483_1_mek,TA,DOMAIN,Domain Abbreviation,Char,11,0,TA,,TA,TA,TA,TA,TA,TA,TA,TA,TA
EMD_NCT01016483_1_mek,TA,ARMCD,Planned Arm Code,Char,11,0,A,,A,A,A,A,A,A,B,B,B
EMD_NCT01016483_1_mek,TA,ARM,Description of Planned Arm,Char,11,0,Arm 1: Gemcitabine and Placebo,,Arm 1: Gemcitabine and Placebo,Arm 1: Gemcitabine and Placebo,Arm 1: Gemcitabine and Placebo,Arm 1: Gemcitabine and Placebo,Arm 1: Gemcitabine and Placebo,Arm 1: Gemcitabine and Placebo,Arm 2: Gemcitabine and Pimasertib,Arm 2: Gemcitabine and Pimasertib,Arm 2: Gemcitabine and Pimasertib
EMD_NCT01016483_1_mek,TA,TAETORD,Order of Element within Arm,Num,11,0,1,.,1,2,2,3,3,4,4,5,7
EMD_NCT01016483_1_mek,TA,ETCD,Element Code,Char,11,0,FU,,FU,MONOTHER,MPTP,MSCRN,PTP,PTP,SCRN,SCRN,TRT_PLA
EMD_NCT01016483_1_mek,TA,ELEMENT,Description of Element,Char,11,0,Follow-up Period,,Follow-up Period,Gemcitabine and Pimasertib,Gemcitabine and Placebo,Monotherapy Post Treatment Period,Monotherapy Screening,Pimasertib Monotherapy,Post Treatment Period,Post Treatment Period,Screening
EMD_NCT01016483_1_mek,TA,TABRANCH,Branch,Char,3,8,Assigned to Pimasertib Monotherapy,,,,,,,Randomized to Gemcitabine and Pimasertib,,,Randomized to Gemcitabine and Placebo
EMD_NCT01016483_1_mek,TA,TATRANS,Transition Rule,Char,1,10,"Treatment failure, disease progression",,,,,,,,,,
EMD_NCT01016483_1_mek,TA,EPOCH,Epoch,Char,11,0,FOLLOW-UP,,FOLLOW-UP,MONOTHERAPY POST TREATMENT,MONOTHERAPY SCREENING,MONOTHERAPY TREATMENT,POST TREATMENT,POST TREATMENT,SCREENING,SCREENING,TREATMENT
EMD_NCT01016483_1_mek,TE,STUDYID,Study Identifier,Char,8,0,0200066003,,,0200066003,0200066003,0200066003,,0200066003,0200066003,0200066003,0200066003
EMD_NCT01016483_1_mek,TE,DOMAIN,Domain Abbreviation,Char,8,0,TE,,,TE,TE,TE,,TE,TE,TE,TE
EMD_NCT01016483_1_mek,TE,ETCD,Element Code,Char,8,0,FU,,,MONOTHER,MPTP,MSCRN,,PTP,SCRN,TRT_PIM,TRT_PLA
EMD_NCT01016483_1_mek,TE,ELEMENT,Description of Element,Char,8,0,Follow-up Period,,,Gemcitabine and Pimasertib,Gemcitabine and Placebo,Monotherapy Post Treatment Period,,Monotherapy Screening,Pimasertib Monotherapy,Post Treatment Period,Screening
EMD_NCT01016483_1_mek,TE,TESTRL,Rule for Start of Element,Char,8,0,First dose of Gemcitabine and Pimasertib,,,First dose of Gemcitabine and Placebo,First dose of Pimasertib Monotherapy,First follow-up date,,Informed consent,Last double blind dose,Last monotherapy dose,Monotherapy screening date
EMD_NCT01016483_1_mek,TI,STUDYID,Study Identifier,Char,24,0,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003
EMD_NCT01016483_1_mek,TI,DOMAIN,Domain Abbreviation,Char,24,0,TI,TI,TI,TI,TI,TI,TI,TI,TI,TI,TI
EMD_NCT01016483_1_mek,TI,IETESTCD,Incl/Excl Criterion Short Name,Char,24,0,EXCL01,EXCL02,EXCL04,EXCL07,EXCL09,EXCL12,EXCL14,EXCL16,INCL01,INCL03,INCL06
EMD_NCT01016483_1_mek,TI,IETEST,Inclusion/Exclusion Criterion,Char,24,0,Age >= 18 years.,"Bone marrow impairment as evidenced by hemoglobin < 9.0 g/dL, neutrophil count < 1.5 x 109/L, platelets < 100 x 109/L.",Evidence of disease (not necessarily measurable disease). Complete tumor assessment including scans documenting all sites of disease performed within 28 days prior to trial entry/randomization.,"Extensive prior radiotherapy on > 30% of bone marrow reserves, or prior bone marrow/stem cell transplantation. Prior radiation is allowed if completed >= 4 weeks before trial entry/randomization.",Histologically or cytologically confirmed metastatic adenocarcinoma of the pancreas and availability of tumor sample.,"History of difficulty swallowing, malabsorption or other chronic gastro-intestinal disease or conditions that may hamper compliance and/or absorption of the tested product.",Known hypersensitivity to the MSC1936369B or gemcitabine.,Participation in another clinical trial within the past 28 days.,"Renal impairment as evidenced by serum creatinine > 1.5 x upper limit of normal (ULN), and/or calculated creatinine clearance < 60 mL/min.",Serum calcium > 1 x ULN.,"Women of childbearing potential (all female subjects unless post-menopausal for >= two years, surgically sterile or sexually inactive) must have a negative blood pregnancy test at screening visit."
EMD_NCT01016483_1_mek,TI,IECAT,Inclusion/Exclusion Category,Char,24,0,EXCLUSION,EXCLUSION,EXCLUSION,EXCLUSION,EXCLUSION,EXCLUSION,EXCLUSION,EXCLUSION,INCLUSION,INCLUSION,INCLUSION
EMD_NCT01016483_1_mek,TI,IESCAT,Inclusion/Exclusion Subcategory,Char,24,0,MSC1936369B MONOTHERAPY,MSC1936369B MONOTHERAPY,RANDOMIZED PHASE II PART,RANDOMIZED PHASE II PART,RANDOMIZED PHASE II PART,RANDOMIZED PHASE II PART,RANDOMIZED PHASE II PART,RANDOMIZED PHASE II PART,RANDOMIZED PHASE II PART,RANDOMIZED PHASE II PART,RANDOMIZED PHASE II PART
EMD_NCT01016483_1_mek,TR,STUDYID,Study Identifier,Char,1104,0,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003
EMD_NCT01016483_1_mek,TR,DOMAIN,Domain Abbreviation,Char,1104,0,TR,TR,TR,TR,TR,TR,TR,TR,TR,TR,TR
EMD_NCT01016483_1_mek,TR,USUBJID,Unique Subject Identifier,Char,1104,0,1,5,10,16,22,26,32,36,39,41,44
EMD_NCT01016483_1_mek,TR,TRSEQ,Sequence Number,Num,1104,0,1,3,6,8,11,15,19,25,32,41,65
EMD_NCT01016483_1_mek,TR,TRGRPID,Group ID,Char,1104,0,CYCLE 1,CYCLE 1,CYCLE 1,CYCLE 3,CYCLE 3,CYCLE 7,MONOTHERAPY CYCLE 2,SCREENING,SCREENING,SCREENING,UNSCHEDULED 02
EMD_NCT01016483_1_mek,TR,TRSPID,Sponsor-Defined Identifier,Char,1104,0,1,1,1,1,2,2,2,3,3,4,9
EMD_NCT01016483_1_mek,TR,TRLNKID,Link ID,Char,1104,0,NEW01,NT01,NT02,T01,T01,T01,T02,T02,T03,T04,T08
EMD_NCT01016483_1_mek,TR,TRLNKGRP,Link Group,Char,1104,0,NEWCYCLE 1,NTCYCLE 13,NTSCREENING,TCYCLE 1,TCYCLE 1,TCYCLE 3,TCYCLE 5,TMONOTHERAPY CYCLE 2,TSCREENING,TSCREENING,TUNSCHEDULED 02
EMD_NCT01016483_1_mek,TR,TRTESTCD,Tumor Assessment Short Name,Char,1104,0,LDIAM,LDIAM,LDIAM,LDIAM,SUMLDIAM,SUMLDIAM,SUMLDIAM,SUMLDIAM,TUMSTATE,TUMSTATE,TUMSTATE
EMD_NCT01016483_1_mek,TR,TRTEST,Tumor Assessment Test Name,Char,1104,0,Longest Diameter,Longest Diameter,Longest Diameter,Longest Diameter,Sum of Longest Diameter,Sum of Longest Diameter,Sum of Longest Diameter,Sum of Longest Diameter,Tumor State,Tumor State,Tumor State
EMD_NCT01016483_1_mek,TR,TRORRES,Result or Finding in Original Units,Char,1101,3,0,113,14,22,35,52,72,9,NOT APPLICABLE,"PERSISTENT, BUT NOT PROGRESSING",UNEQUIVOCAL PROGRESSION
EMD_NCT01016483_1_mek,TR,TRORRESU,Original Units,Char,804,300,mm,mm,mm,mm,mm,mm,mm,mm,mm,mm,mm
EMD_NCT01016483_1_mek,TR,TRSTRESC,Character Result/Finding in Std Format,Char,1101,3,0,113,14,22,35,52,72,9,NOT APPLICABLE,"PERSISTENT, BUT NOT PROGRESSING",UNEQUIVOCAL PROGRESSION
EMD_NCT01016483_1_mek,TR,TRSTRESN,Numeric Result/Finding in Standard Units,Num,804,300,0,10,14,22,35,47,64,80,101,126,237
EMD_NCT01016483_1_mek,TR,TRSTRESU,Standard Units,Char,804,300,mm,mm,mm,mm,mm,mm,mm,mm,mm,mm,mm
EMD_NCT01016483_1_mek,TR,TRMETHOD,Method used to Identify the Tumor,Char,1104,0,CT,MRI,MSCT,MSCT,SPIRAL CT,SPIRAL CT,SPIRAL CT,SPIRAL CT,SPIRAL CT,SPIRAL CT,SPIRAL CT
EMD_NCT01016483_1_mek,TR,VISITNUM,Visit Number,Num,1104,0,1,1,1,1,156,156,328,328,728,16777,99994
EMD_NCT01016483_1_mek,TR,VISIT,Visit Name,Char,1104,0,CYCLE 1 DAY 56,CYCLE 1 DAY 56,CYCLE 1 DAY 56,CYCLE 3 DAY 28,CYCLE 3 DAY 28,CYCLE 5 DAY 28,END OF TREATMENT,SCREENING,SCREENING,SCREENING,STUDY TERMINATION UNSCHEDULED 1
EMD_NCT01016483_1_mek,TR,VISITDY,Planned Study Day of Visit,Num,1007,97,-28,-28,-28,-28,56,56,112,112,168,280,2056
EMD_NCT01016483_1_mek,TR,ETCD,Element Code,Char,1055,49,FU,PTP,SCRN,SCRN,SCRN,TRT_PLA,TRT_PLA,TRT_PLA,TRT_PLA,TRT_PLA,TRT_PLA
EMD_NCT01016483_1_mek,TR,ELEMENT,Description of Element,Char,1055,49,Follow-up Period,Gemcitabine and Placebo,Gemcitabine and Placebo,Gemcitabine and Placebo,Gemcitabine and Placebo,Gemcitabine and Placebo,Monotherapy Post Treatment Period,Post Treatment Period,Screening,Screening,Screening
EMD_NCT01016483_1_mek,TR,EPOCH,Epoch,Char,1055,49,FOLLOW-UP,POST TREATMENT,SCREENING,SCREENING,SCREENING,TREATMENT,TREATMENT,TREATMENT,TREATMENT,TREATMENT,TREATMENT
EMD_NCT01016483_1_mek,TR,TRDTC,Date/Time of Tumor Measurement,Char,1104,0,******,2013-05-19,2013-07-07,2013-08-01,2013-08-28,2013-09-21,2013-10-24,2013-12-09,2014-01-26,2014-04-06,2015-02-09
EMD_NCT01016483_1_mek,TR,TRDY,Study Day of Tumor Measurement,Num,1097,7,-27,-9,-6,-1,50,54,105,114,169,240,611
EMD_NCT01016483_1_mek,TS,STUDYID,Study Identifier,Char,72,0,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003
EMD_NCT01016483_1_mek,TS,DOMAIN,Domain Abbreviation,Char,72,0,TS,TS,TS,TS,TS,TS,TS,TS,TS,TS,TS
EMD_NCT01016483_1_mek,TS,TSSEQ,Sequence Number,Num,72,0,1,1,1,1,1,1,2,2,4,5,9
EMD_NCT01016483_1_mek,TS,TSGRPID,Group ID,Char,10,62,GEMCITABINE,,GEMCITABINE,GEMCITABINE,GEMCITABINE,GEMCITABINE,PIMASERTIB,PIMASERTIB,PIMASERTIB,PIMASERTIB,PIMASERTIB
EMD_NCT01016483_1_mek,TS,TSPARMCD,Trial Summary Parameter Short Name,Char,72,0,ADDON,DOSE,HLTSUBJI,OBJSEC,OUTMSSEC,OUTMSSEC,PLANSUB,SEXPOP,STOPRULE,TDIGRP,TTYPE
EMD_NCT01016483_1_mek,TS,TSPARM,Trial Summary Parameter,Char,72,0,Added on to Existing Treatments,Diagnosis Group,Healthy Subject Indicator,Planned Number of Subjects,Secondary Outcome Measure,Sex of Participants,Study Stop Rules,Tertiary Outcome Measure,Trial Length,Trial Tertiary Objective,Trial is Randomized
EMD_NCT01016483_1_mek,TS,TSVAL,Parameter Value,Char,70,2,1000,2011-09-12,Country,"For subjects receiving subsequent MSC1936369B monotherapy after treatment failure in Arm 1: Best overall response, clinical benefit, PFS, TTP and OS calculated from the first dose of MSC1936369B in",Metastatic pancreas cancer,"Overall survival (OS) time, defined as the time (in months) from randomization to death (as found in the clinical database).",Phase II randomized trial of MEK inhibitor MSC1936369B or placebo combined with gemcitabine in metastatic pancreas cancer subjects,Sponsor's decision that continuation of the trial is unjustifiable for medical or ethical reasons.,"To evaluate the anti-tumor activity in each treatment arm in terms of response rate, clinical benefit, overall survival and time to progression.",Twice daily,mg/m2
EMD_NCT01016483_1_mek,TS,TSVAL1,Parameter Value (1),Char,5,67,documented by the Investigator (i.e. radiological progression per RECIST).,,,,dose of MSC1936369B for subjects in the monotherapy part.,,the Investigator (i.e. radiological progression per RECIST criteria).,,the monotherapy part.,,volume of peripheral compartment V2/f)
EMD_NCT01016483_1_mek,TS,TSVALNF,Parameter Null Flavor,Char,4,68,NA,,,,,NA,,,NA,,PINF
EMD_NCT01016483_1_mek,TS,TSVALCD,Parameter Value Code,Char,16,56,C15228,,C28253,C29848,C38288,C49487,C49488,C49648,C49663,C49667,C67402
EMD_NCT01016483_1_mek,TS,TSVCDREF,Name of the Reference Terminology,Char,19,53,CDISC,,CDISC,CDISC,CDISC,CDISC,CDISC,CDISC,CDISC,CDISC,ISO 8601
EMD_NCT01016483_1_mek,TS,TSVCDVER,Version of the Reference Terminology,Char,16,56,2012-12-21,,2012-12-21,2012-12-21,2012-12-21,2012-12-21,2012-12-21,2012-12-21,2012-12-21,2012-12-21,2012-12-21
EMD_NCT01016483_1_mek,TU,STUDYID,Study Identifier,Char,703,0,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003
EMD_NCT01016483_1_mek,TU,DOMAIN,Domain Abbreviation,Char,703,0,TU,TU,TU,TU,TU,TU,TU,TU,TU,TU,TU
EMD_NCT01016483_1_mek,TU,USUBJID,Unique Subject Identifier,Char,703,0,1,5,10,16,21,26,32,37,39,42,44
EMD_NCT01016483_1_mek,TU,TUSEQ,Sequence Number,Num,703,0,1,2,4,6,7,10,12,16,20,26,37
EMD_NCT01016483_1_mek,TU,TUGRPID,Group ID,Char,703,0,CYCLE 1,CYCLE 1,CYCLE 1,CYCLE 3,CYCLE 3,CYCLE 7,FINAL ASSESSMENT,SCREENING,SCREENING,SCREENING,UNSCHEDULED 02
EMD_NCT01016483_1_mek,TU,TUSPID,Sponsor-Defined Identifier,Char,703,0,1,1,1,1,1,2,2,3,3,4,9
EMD_NCT01016483_1_mek,TU,TULNKID,Link ID,Char,703,0,NEW01,NT01,NT01,NT02,NT07,T01,T01,T02,T03,T03,T08
EMD_NCT01016483_1_mek,TU,TUTESTCD,Tumor Identification Short Name,Char,703,0,TUMIDENT,TUMIDENT,TUMIDENT,TUMIDENT,TUMIDENT,TUMIDENT,TUMIDENT,TUMIDENT,TUMIDENT,TUMIDENT,TUMIDENT
EMD_NCT01016483_1_mek,TU,TUTEST,Tumor Identification Test Name,Char,703,0,Tumor Identification,Tumor Identification,Tumor Identification,Tumor Identification,Tumor Identification,Tumor Identification,Tumor Identification,Tumor Identification,Tumor Identification,Tumor Identification,Tumor Identification
EMD_NCT01016483_1_mek,TU,TUORRES,Tumor Identification Result,Char,703,0,NEW,NON-TARGET,NON-TARGET,NON-TARGET,NON-TARGET,TARGET,TARGET,TARGET,TARGET,TARGET,TARGET
EMD_NCT01016483_1_mek,TU,TUSTRESC,Tumor Identification Result Std. Format,Char,703,0,NEW,NON-TARGET,NON-TARGET,NON-TARGET,NON-TARGET,TARGET,TARGET,TARGET,TARGET,TARGET,TARGET
EMD_NCT01016483_1_mek,TU,TURESCAT,Tumor Identification Result Category,Char,703,0,METASTASIS,METASTASIS,METASTASIS,METASTASIS,METASTASIS,METASTASIS,METASTASIS,METASTASIS,NODE,PRIMARY,PRIMARY
EMD_NCT01016483_1_mek,TU,TULOC,Location of the Tumor,Char,703,0,ADRENAL: LEFT,LIVER: LEFT LOBE,LIVER: NEXT TO VENA CAVA INFERIOR,LIVER: S6,LIVER: SEGMENT 1,LIVER: SEGMENT VI,LUNG: METASTASIS,OTHER: TUMORAL INFILTRATION OF SUPERIOR MESENTERIC VEINA,PANCREAS: BODY AND TAIL,PARA-AORTIC NODES,SUPERIOR MESENTERIC ARTERY NODE
EMD_NCT01016483_1_mek,TU,TUMETHOD,Method of Identification,Char,703,0,CT,MSCT,MSCT,SPIRAL CT,SPIRAL CT,SPIRAL CT,SPIRAL CT,SPIRAL CT,SPIRAL CT,SPIRAL CT,SPIRAL CT
EMD_NCT01016483_1_mek,TU,VISITNUM,Visit Number,Num,703,0,1,1,1,156,156,156,328,422.01,728,16777,99994
EMD_NCT01016483_1_mek,TU,VISIT,Visit Name,Char,703,0,CYCLE 1 DAY 56,CYCLE 1 DAY 56,CYCLE 1 DAY 56,CYCLE 3 DAY 28,CYCLE 3 DAY 28,CYCLE 5 DAY 28,END OF TREATMENT,SCREENING,SCREENING,SCREENING,STUDY TERMINATION UNSCHEDULED 1
EMD_NCT01016483_1_mek,TU,VISITDY,Planned Study Day of Visit,Num,631,72,-28,-28,-28,-28,56,56,112,112,168,280,2056
EMD_NCT01016483_1_mek,TU,ETCD,Element Code,Char,669,34,FU,PTP,SCRN,SCRN,SCRN,TRT_PLA,TRT_PLA,TRT_PLA,TRT_PLA,TRT_PLA,TRT_PLA
EMD_NCT01016483_1_mek,TU,ELEMENT,Description of Element,Char,669,34,Follow-up Period,Gemcitabine and Placebo,Gemcitabine and Placebo,Gemcitabine and Placebo,Gemcitabine and Placebo,Gemcitabine and Placebo,Monotherapy Post Treatment Period,Post Treatment Period,Screening,Screening,Screening
EMD_NCT01016483_1_mek,TU,EPOCH,Epoch,Char,669,34,FOLLOW-UP,POST TREATMENT,SCREENING,SCREENING,SCREENING,TREATMENT,TREATMENT,TREATMENT,TREATMENT,TREATMENT,TREATMENT
EMD_NCT01016483_1_mek,TU,TUDTC,Date/Time of Tumor Identification,Char,703,0,******,2013-05-17,2013-07-07,2013-07-28,2013-08-28,2013-09-20,2013-10-24,2013-12-09,2014-01-28,2014-04-06,2015-02-09
EMD_NCT01016483_1_mek,TU,TUDY,Study Day of Tumor Identification,Num,695,8,-27,-8,-5,8,50,54,105,114,170,268,611
EMD_NCT01016483_1_mek,TV,STUDYID,Study Identifier,Char,242,0,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003
EMD_NCT01016483_1_mek,TV,DOMAIN,Domain Abbreviation,Char,242,0,TV,TV,TV,TV,TV,TV,TV,TV,TV,TV,TV
EMD_NCT01016483_1_mek,TV,VISITNUM,Visit Number,Num,242,0,1,150,408,701,922,1215,1508,1728,2015,20108,99995
EMD_NCT01016483_1_mek,TV,VISIT,Visit Name,Char,242,0,CYCLE 1 DAY 1,CYCLE 1 DAY 8,CYCLE 12 DAY 22,CYCLE 15 DAY 15,CYCLE 17 DAY 8,CYCLE 2 DAY 8,CYCLE 3 DAY 22,CYCLE 6 DAY 1,CYCLE 8 DAY 8,MONOTHERAPY CYCLE 2 DAY 22,TREATMENT TERMINATION
EMD_NCT01016483_1_mek,TV,VISITDY,Planned Study Day of Visit,Num,226,16,-28,47,113,183,253,330,393,463,533,610,2127
EMD_NCT01016483_1_mek,TV,ARMCD,Planned Arm Code,Char,242,0,A,A,A,A,A,A,B,B,B,B,B
EMD_NCT01016483_1_mek,TV,ARM,Description of Planned Arm,Char,242,0,Arm 1: Gemcitabine and Placebo,Arm 1: Gemcitabine and Placebo,Arm 1: Gemcitabine and Placebo,Arm 1: Gemcitabine and Placebo,Arm 1: Gemcitabine and Placebo,Arm 1: Gemcitabine and Placebo,Arm 2: Gemcitabine and Pimasertib,Arm 2: Gemcitabine and Pimasertib,Arm 2: Gemcitabine and Pimasertib,Arm 2: Gemcitabine and Pimasertib,Arm 2: Gemcitabine and Pimasertib
EMD_NCT01016483_1_mek,TV,TVSTRL,Visit Start Rule,Char,242,0,Day 1 of Monotherapy Treatment Epoch,Day 15 of Monotherapy Treatment Epoch,Day 211 of Treatment Epoch,Day 274 of Treatment Epoch,Day 336 of Treatment Epoch,Day 400 of Treatment Epoch,Day 47 of Treatment Epoch,Day 526 of Treatment Epoch,Day 582 of Treatment Epoch,Day 85 of Treatment Epoch,Within 30 +/- 3 days after end of Treatment Epoch
EMD_NCT01016483_1_mek,VS,STUDYID,Study Identifier,Char,9246,0,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003
EMD_NCT01016483_1_mek,VS,DOMAIN,Domain Abbreviation,Char,9246,0,VS,VS,VS,VS,VS,VS,VS,VS,VS,VS,VS
EMD_NCT01016483_1_mek,VS,USUBJID,Unique Subject Identifier,Char,9246,0,1,5,8,13,18,22,27,33,37,41,44
EMD_NCT01016483_1_mek,VS,VSSEQ,Sequence Number,Num,9246,0,1,21,43,65,87,112,139,167,201,256,476
EMD_NCT01016483_1_mek,VS,VSTESTCD,Vital Signs Test Short Name,Char,9246,0,DIABP,DIABP,DIABP,PULSE,PULSE,PULSE,SYSBP,SYSBP,SYSBP,TEMP,WEIGHT
EMD_NCT01016483_1_mek,VS,VSTEST,Vital Signs Test Name,Char,9246,0,Diastolic Blood Pressure,Diastolic Blood Pressure,Diastolic Blood Pressure,Pulse Rate,Pulse Rate,Pulse Rate,Systolic Blood Pressure,Systolic Blood Pressure,Systolic Blood Pressure,Temperature,Weight
EMD_NCT01016483_1_mek,VS,VSPOS,Vital Signs Position of Subject,Char,7652,1594,SITTING,SITTING,SITTING,SITTING,SITTING,SITTING,SITTING,SITTING,SITTING,SITTING,SITTING
EMD_NCT01016483_1_mek,VS,VSORRES,Result or Finding in Original Units,Char,8778,468,100,120,131,36.1,56,65,70,74,79,83,99
EMD_NCT01016483_1_mek,VS,VSORRESU,Original Units,Char,8777,469,BEATS/MIN,BEATS/MIN,BEATS/MIN,C,kg,mmHg,mmHg,mmHg,mmHg,mmHg,mmHg
EMD_NCT01016483_1_mek,VS,VSSTRESC,Character Result/Finding in Std Format,Char,8778,468,100,120,131,36.1,56,65,70,74,79,83,99
EMD_NCT01016483_1_mek,VS,VSSTRESN,Numeric Result/Finding in Standard Units,Num,8778,468,34.6,54,64,70,74,78,82,95,120,130,207
EMD_NCT01016483_1_mek,VS,VSSTRESU,Standard Units,Char,8778,468,BEATS/MIN,BEATS/MIN,BEATS/MIN,C,kg,mmHg,mmHg,mmHg,mmHg,mmHg,mmHg
EMD_NCT01016483_1_mek,VS,VSSTAT,Completion Status,Char,468,8778,NOT DONE,NOT DONE,NOT DONE,NOT DONE,NOT DONE,NOT DONE,NOT DONE,NOT DONE,NOT DONE,NOT DONE,NOT DONE
EMD_NCT01016483_1_mek,VS,VSREASND,Reason Not Performed,Char,468,8778,NOT COLLECTED ON CRF,NOT COLLECTED ON CRF,NOT COLLECTED ON CRF,NOT COLLECTED ON CRF,NOT COLLECTED ON CRF,NOT COLLECTED ON CRF,NOT COLLECTED ON CRF,NOT COLLECTED ON CRF,NOT COLLECTED ON CRF,NOT COLLECTED ON CRF,NOT COLLECTED ON CRF
EMD_NCT01016483_1_mek,VS,VSBLFL,Baseline Flag,Char,265,8981,Y,Y,Y,Y,Y,Y,Y,Y,Y,Y,Y
EMD_NCT01016483_1_mek,VS,VISITNUM,Visit Number,Num,9246,0,1,101,102,108,122,129,136,147,415,2001,26877
EMD_NCT01016483_1_mek,VS,VISIT,Visit Name,Char,9246,0,CYCLE 1 DAY 1,CYCLE 1 DAY 1,CYCLE 1 DAY 15,CYCLE 1 DAY 22,CYCLE 1 DAY 29,CYCLE 1 DAY 36,CYCLE 1 DAY 47,CYCLE 11 DAY 1,CYCLE 4 DAY 15,MONOTHERAPY CYCLE 1 DAY 1,TREATMENT TERMINATION UNSCHEDULED 3
EMD_NCT01016483_1_mek,VS,VISITDY,Planned Study Day of Visit,Num,8943,303,-28,1,2,8,15,29,36,47,99,288,2085
EMD_NCT01016483_1_mek,VS,ETCD,Element Code,Char,8952,294,FU,SCRN,TRT_PLA,TRT_PLA,TRT_PLA,TRT_PLA,TRT_PLA,TRT_PLA,TRT_PLA,TRT_PLA,UNPLAN
EMD_NCT01016483_1_mek,VS,ELEMENT,Description of Element,Char,8944,302,Follow-up Period,Gemcitabine and Placebo,Gemcitabine and Placebo,Gemcitabine and Placebo,Gemcitabine and Placebo,Gemcitabine and Placebo,Gemcitabine and Placebo,Gemcitabine and Placebo,Gemcitabine and Placebo,Pimasertib Monotherapy,Screening
EMD_NCT01016483_1_mek,VS,EPOCH,Epoch,Char,8952,294,FOLLOW-UP,SCREENING,TREATMENT,TREATMENT,TREATMENT,TREATMENT,TREATMENT,TREATMENT,TREATMENT,TREATMENT,TREATMENT
EMD_NCT01016483_1_mek,VS,VSDTC,Date/Time of Measurements,Char,9246,0,******,2013-04-19T13:18:00,2013-06-10T11:35:00,2013-07-09T17:10:00,2013-07-27T10:02:00,2013-08-19T08:30:00,2013-09-08T11:25:00,2013-10-08T16:00:00,2013-11-11T11:37:00,2014-01-27T08:00:00,2015-03-16
EMD_NCT01016483_1_mek,VS,VSDY,Study Day of Vital Signs,Num,8936,310,-29,1,2,8,16,29,36,47,99,198,646
EMD_NCT01016483_1_mek,VS,VSTPT,Planned Time Point Name,Char,6946,2300,1 HOUR POST DOSE,1 HOUR POST DOSE,2 HOURS POST DOSE,2 HOURS POST DOSE,3 HOURS POST DOSE,30 MINUTES POST DOSE,30 MINUTES POST DOSE,4 HOURS POST DOSE,5 HOURS POST DOSE,PRE-DOSE,PRE-DOSE
EMD_NCT01016483_1_mek,VS,VSTPTNUM,Planned Time Point Number,Num,6946,2300,0,0,30,30,100,200,200,300,300,400,600
EMD_NCT01016483_1_mek,VS,VSELTM,Planned Elapsed Time from Time Point Ref,Char,6946,2300,-PT5M,-PT5M,PT1H,PT1H,PT2H,PT30M,PT30M,PT3H,PT3H,PT4H,PT6H
EMD_NCT01016483_1_mek,VS,VSTPTREF,Time Point Reference,Char,6946,2300,AM DOSE OF PIMASERTIB,AM DOSE OF PLACEBO,AM DOSE OF PLACEBO,AM DOSE OF PLACEBO,AM DOSE OF PLACEBO,AM DOSE OF PLACEBO,AM DOSE OF PLACEBO,AM DOSE OF PLACEBO,AM DOSE OF PLACEBO,AM DOSE OF PLACEBO,AM DOSE OF PLACEBO
EMD_NCT01016483_1_mek,VS,VSRFTDTC,Date/Time of Reference Time Point,Char,9246,0,******,******,******,******,2013-04-26T10:05,2013-06-25T12:00,2013-07-20T08:00,2013-08-13T09:00,2013-09-07T10:00,2013-10-24T10:10,2014-08-19T15:38
EMD_NCT01016483_1_mek,XP,STUDYID,Study Identifier,Char,328,0,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003
EMD_NCT01016483_1_mek,XP,DOMAIN,Domain Abbreviation,Char,328,0,XP,XP,XP,XP,XP,XP,XP,XP,XP,XP,XP
EMD_NCT01016483_1_mek,XP,USUBJID,Unique Subject Identifier,Char,328,0,1,5,7,11,18,21,26,33,37,41,44
EMD_NCT01016483_1_mek,XP,XPSEQ,Sequence Number,Num,328,0,1,1,2,3,4,5,6,7,9,12,25
EMD_NCT01016483_1_mek,XP,XPTESTCD,Performance Status Short Name,Char,328,0,ECOG,ECOG,ECOG,ECOG,ECOG,ECOG,ECOG,ECOG,ECOG,ECOG,ECOG
EMD_NCT01016483_1_mek,XP,XPTEST,Performance Status Name,Char,328,0,ECOG,ECOG,ECOG,ECOG,ECOG,ECOG,ECOG,ECOG,ECOG,ECOG,ECOG
EMD_NCT01016483_1_mek,XP,XPORRES,Result or Finding in Original Units,Char,0,328,,,,,,,,,,,
EMD_NCT01016483_1_mek,XP,XPSTRESC,Character Result/Finding in Std Format,Char,0,328,,,,,,,,,,,
EMD_NCT01016483_1_mek,XP,XPSTRESN,Numeric Result/Finding in Standard Units,Num,328,0,0,0,0,0,0,1,1,1,1,1,5
EMD_NCT01016483_1_mek,XP,XPBLFL,Baseline Flag,Char,43,285,Y,Y,Y,Y,Y,Y,Y,Y,Y,Y,Y
EMD_NCT01016483_1_mek,XP,VISITNUM,Visit Number,Num,328,0,1,1,101,129,201,301,601,1101,16777,20001,26877
EMD_NCT01016483_1_mek,XP,VISIT,Visit Name,Char,328,0,CYCLE 1 DAY 1,CYCLE 1 DAY 1,CYCLE 1 DAY 29,CYCLE 17 DAY 1,CYCLE 3 DAY 1,CYCLE 5 DAY 1,CYCLE 8 DAY 1,END OF TREATMENT,MONOTHERAPY SCREENING,SCREENING,TREATMENT TERMINATION UNSCHEDULED 3
EMD_NCT01016483_1_mek,XP,VISITDY,Planned Study Day of Visit,Num,277,51,-28,-28,1,1,29,57,113,169,253,2000,2085
EMD_NCT01016483_1_mek,XP,ETCD,Element Code,Char,323,5,FU,MSCRN,PTP,SCRN,TRT_PLA,TRT_PLA,TRT_PLA,TRT_PLA,TRT_PLA,TRT_PLA,UNPLAN
EMD_NCT01016483_1_mek,XP,ELEMENT,Description of Element,Char,322,6,Follow-up Period,Gemcitabine and Placebo,Gemcitabine and Placebo,Gemcitabine and Placebo,Gemcitabine and Placebo,Gemcitabine and Placebo,Gemcitabine and Placebo,Pimasertib Monotherapy,Post Treatment Period,Screening,Screening
EMD_NCT01016483_1_mek,XP,EPOCH,Epoch,Char,323,5,FOLLOW-UP,MONOTHERAPY TREATMENT,POST TREATMENT,SCREENING,TREATMENT,TREATMENT,TREATMENT,TREATMENT,TREATMENT,TREATMENT,TREATMENT
EMD_NCT01016483_1_mek,XP,XPDTC,Date/Time of Performance Status,Char,328,0,******,2013-05-10,2013-06-29,2013-07-25,2013-08-27,2013-09-27,2013-10-28,2013-12-12,2014-02-11,2014-05-12,2015-03-16
EMD_NCT01016483_1_mek,XP,XPDY,Study Day of Performance Status,Num,321,7,-29,-6,1,29,57,77,113,141,199,281,646
EMD_NCT01016483_1_mek,XX,STUDYID,Study Identifier,Char,1486,0,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003
EMD_NCT01016483_1_mek,XX,DOMAIN,Domain Abbreviation,Char,1486,0,XX,XX,XX,XX,XX,XX,XX,XX,XX,XX,XX
EMD_NCT01016483_1_mek,XX,USUBJID,Unique Subject Identifier,Char,1486,0,1,5,7,11,17,21,26,33,37,41,44
EMD_NCT01016483_1_mek,XX,XXSEQ,Sequence Number,Num,1486,0,1,4,7,11,15,21,27,36,47,65,137
EMD_NCT01016483_1_mek,XX,XXREFID,Study Maintenance Reference ID,Char,1291,195,1,11,15,2,25,30,4,49,6,74,99
EMD_NCT01016483_1_mek,XX,XXTESTCD,Study Maintenance Short Name,Char,1486,0,BIOMARK,NUMBER,NUMBER,NUMBER,NUMBER,NUMBER,NUMBER,NUMBER,NUMBER,NUMBER,XRAY
EMD_NCT01016483_1_mek,XX,XXTEST,Study Maintenance Name,Char,1486,0,Candidate PGx Markers,Kit Number,Kit Number,Kit Number,Kit Number,Kit Number,Kit Number,Kit Number,Kit Number,Kit Number,Physical Examination
EMD_NCT01016483_1_mek,XX,XXCAT,Category for Study Maintenance,Char,1486,0,CHEST IMAGE,PHYSICAL EXAMINATION,TREATMENT PLACEBO KIT NUMBER,TREATMENT PLACEBO KIT NUMBER,TREATMENT PLACEBO KIT NUMBER,TREATMENT PLACEBO KIT NUMBER,TREATMENT PLACEBO KIT NUMBER,TREATMENT PLACEBO KIT NUMBER,TREATMENT PLACEBO KIT NUMBER,TREATMENT PLACEBO KIT NUMBER,TREATMENT PLACEBO KIT NUMBER
EMD_NCT01016483_1_mek,XX,XXORRES,Result or Finding in Original Units,Char,1291,195,10139,20394,20694,21012,21371,21680,23370,23711,24022,25420,73380
EMD_NCT01016483_1_mek,XX,XXSTRESC,Character Result/Finding in Std Format,Char,1291,195,10139,20394,20694,21012,21371,21680,23370,23711,24022,25420,73380
EMD_NCT01016483_1_mek,XX,XXSTAT,Completion Status,Char,109,1377,NOT DONE,NOT DONE,NOT DONE,NOT DONE,NOT DONE,NOT DONE,NOT DONE,NOT DONE,NOT DONE,NOT DONE,NOT DONE
EMD_NCT01016483_1_mek,XX,XXREASND,Reason Study Maintenance Not Performed,Char,109,1377,NOT COLLECTED ON CRF,NOT COLLECTED ON CRF,NOT COLLECTED ON CRF,NOT COLLECTED ON CRF,NOT COLLECTED ON CRF,NOT COLLECTED ON CRF,NOT COLLECTED ON CRF,NOT COLLECTED ON CRF,NOT COLLECTED ON CRF,NOT COLLECTED ON CRF,NOT COLLECTED ON CRF
EMD_NCT01016483_1_mek,XX,XXMETHOD,Method of Measurement,Char,21,1465,CHEST X-RAY,CHEST X-RAY,CHEST X-RAY,CHEST X-RAY,CHEST X-RAY,CHEST X-RAY,CHEST X-RAY,CHEST X-RAY,CHEST X-RAY,CHEST X-RAY,CHEST X-RAY
EMD_NCT01016483_1_mek,XX,VISITNUM,Visit Number,Num,195,1291,1,1,101,101,101,301,16777,16777,16777,16877,26877
EMD_NCT01016483_1_mek,XX,VISIT,Visit Name,Char,1486,0,CYCLE 1,CYCLE 1,CYCLE 1,CYCLE 1,CYCLE 13,CYCLE 2,CYCLE 3,CYCLE 5,CYCLE 7,END OF TREATMENT,SCREENING
EMD_NCT01016483_1_mek,XX,VISITDY,Planned Study Day of Visit,Num,103,1383,-28,-28,1,1,1,1,1,1,1,1,2113
EMD_NCT01016483_1_mek,XX,ETCD,Element Code,Char,119,1367,MONOTHER,PTP,SCRN,SCRN,TRT_PLA,TRT_PLA,TRT_PLA,TRT_PLA,TRT_PLA,TRT_PLA,TRT_PLA
EMD_NCT01016483_1_mek,XX,ELEMENT,Description of Element,Char,119,1367,Gemcitabine and Placebo,Gemcitabine and Placebo,Gemcitabine and Placebo,Gemcitabine and Placebo,Gemcitabine and Placebo,Gemcitabine and Placebo,Gemcitabine and Placebo,Post Treatment Period,Post Treatment Period,Screening,Screening
EMD_NCT01016483_1_mek,XX,EPOCH,Epoch,Char,119,1367,MONOTHERAPY TREATMENT,POST TREATMENT,SCREENING,SCREENING,TREATMENT,TREATMENT,TREATMENT,TREATMENT,TREATMENT,TREATMENT,TREATMENT
EMD_NCT01016483_1_mek,XX,XXDTC,Date/Time of Study Maintenance,Char,1486,0,******,******,******,******,******,******,******,******,******,******,2015-02-16
EMD_NCT01016483_1_mek,XX,XXDY,Study Day of Study Maintenance,Num,119,1367,-27,-6,1,1,1,1,1,1,57,146,618
EMD_NCT01016483_1_mek,YF,STUDYID,Study Identifier,Char,151,0,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003
EMD_NCT01016483_1_mek,YF,DOMAIN,Domain Abbreviation,Char,151,0,YF,YF,YF,YF,YF,YF,YF,YF,YF,YF,YF
EMD_NCT01016483_1_mek,YF,USUBJID,Unique Subject Identifier,Char,151,0,1,6,14,14,18,20,23,26,34,41,44
EMD_NCT01016483_1_mek,YF,YFSEQ,Sequence Number,Num,151,0,1,1,2,3,3,5,6,7,10,13,18
EMD_NCT01016483_1_mek,YF,YFSPID,Sponsor-Defined Identifier,Char,151,0,1,1,1,1,2,2,3,3,4,5,7
EMD_NCT01016483_1_mek,YF,YFTESTCD,Follow-up Result Short Name,Char,151,0,CONFPDC,CONFPDI,CONFPDI,PD,PD,PD,SURVSTAT,SURVSTAT,SURVSTAT,SURVSTAT,SURVSTAT
EMD_NCT01016483_1_mek,YF,YFTEST,Follow-up Result Name,Char,151,0,Disease Progression,Disease Progression,Disease Progression,Disease Progression,Is the Subject Still Alive?,Is the Subject Still Alive?,Is the Subject Still Alive?,Is the Subject Still Alive?,Is the Subject Still Alive?,Progression Confirmed by Imaging,Progression Confirmed by Imaging
EMD_NCT01016483_1_mek,YF,YFORRES,Result or Finding in Original Units,Char,151,0,N,N,U,Y,Y,Y,Y,Y,Y,Y,Y
EMD_NCT01016483_1_mek,YF,YFSTRESC,Character Result/Finding in Std Format,Char,151,0,N,N,U,Y,Y,Y,Y,Y,Y,Y,Y
EMD_NCT01016483_1_mek,YF,VISITNUM,Visit Number,Num,151,0,99995,99995,99995,99995,99995,99995,99995,99995,99995,99995,99995
EMD_NCT01016483_1_mek,YF,VISIT,Visit Name,Char,151,0,FOLLOW UP STATUS,FOLLOW UP STATUS,FOLLOW UP STATUS,FOLLOW UP STATUS,FOLLOW UP STATUS,FOLLOW UP STATUS,FOLLOW UP STATUS,FOLLOW UP STATUS,FOLLOW UP STATUS,FOLLOW UP STATUS,FOLLOW UP STATUS
EMD_NCT01016483_1_mek,YF,ETCD,Element Code,Char,140,11,FU,FU,FU,FU,FU,FU,FU,FU,FU,FU,PTP
EMD_NCT01016483_1_mek,YF,ELEMENT,Description of Element,Char,140,11,Follow-up Period,Follow-up Period,Follow-up Period,Follow-up Period,Follow-up Period,Follow-up Period,Follow-up Period,Follow-up Period,Follow-up Period,Follow-up Period,Post Treatment Period
EMD_NCT01016483_1_mek,YF,EPOCH,Epoch,Char,140,11,FOLLOW-UP,FOLLOW-UP,FOLLOW-UP,FOLLOW-UP,FOLLOW-UP,FOLLOW-UP,FOLLOW-UP,FOLLOW-UP,FOLLOW-UP,FOLLOW-UP,POST TREATMENT
EMD_NCT01016483_1_mek,YF,YFDTC,Date/Time of Follow-up Result,Char,151,0,******,2013-11-20,2013-12-21,2014-01-18,2014-01-31,2014-03-23,2014-05-11,2014-05-25,2014-07-13,2014-10-15,2015-03-04
EMD_NCT01016483_1_mek,YF,YFSTDTC,Start Date/Time of Follow-up Result,Char,151,0,******,******,******,******,******,2013-07-21,2013-12-27,2014-02-21,2014-04-18,2014-07-01,2015-03-04
EMD_NCT01016483_1_mek,YF,YFDY,Study Day of Follow-up Result,Num,149,2,97,147,189,204,246,308,364,393,437,498,549
EMD_NCT01016483_1_mek,YF,YFSTDY,Study Day of Start of Follow-up Result,Num,78,73,50,142,176,204,241,289,330,384,434,490,549
EMD_NCT01016483_1_mek,ZC,STUDYID,Study Identifier,Char,202,0,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003
EMD_NCT01016483_1_mek,ZC,DOMAIN,Domain Abbreviation,Char,202,0,ZC,ZC,ZC,ZC,ZC,ZC,ZC,ZC,ZC,ZC,ZC
EMD_NCT01016483_1_mek,ZC,USUBJID,Unique Subject Identifier,Char,202,0,1,5,7,11,16,21,26,33,36,40,44
EMD_NCT01016483_1_mek,ZC,ZCSEQ,Sequence Number,Num,202,0,1,1,1,2,3,3,4,5,6,8,15
EMD_NCT01016483_1_mek,ZC,ZCTESTCD,Cardiac Assessment Short Name,Char,202,0,LVEF,LVEF,LVEF,LVEF,LVEF,LVEF,LVEF,LVEF,LVEF,LVEF,LVEF
EMD_NCT01016483_1_mek,ZC,ZCTEST,Cardiac Assessment Name,Char,202,0,Left Ventricular Ejection Fraction,Left Ventricular Ejection Fraction,Left Ventricular Ejection Fraction,Left Ventricular Ejection Fraction,Left Ventricular Ejection Fraction,Left Ventricular Ejection Fraction,Left Ventricular Ejection Fraction,Left Ventricular Ejection Fraction,Left Ventricular Ejection Fraction,Left Ventricular Ejection Fraction,Left Ventricular Ejection Fraction
EMD_NCT01016483_1_mek,ZC,ZCCAT,Category for Cardiac Assessment,Char,202,0,ECHOCARDIOGRAM,ECHOCARDIOGRAM,ECHOCARDIOGRAM,ECHOCARDIOGRAM,ECHOCARDIOGRAM,ECHOCARDIOGRAM,ECHOCARDIOGRAM,ECHOCARDIOGRAM,ECHOCARDIOGRAM,MUGA SCAN,MUGA SCAN
EMD_NCT01016483_1_mek,ZC,ZCORRES,Result or Finding in Original Units,Char,197,5,35,55,57,60,60,62,64,65,66,71,82
EMD_NCT01016483_1_mek,ZC,ZCORRESU,Original Units,Char,197,5,%,%,%,%,%,%,%,%,%,%,%
EMD_NCT01016483_1_mek,ZC,ZCSTRESC,Character Result/Finding in Std Format,Char,197,5,35,55,57,60,60,62,64,65,66,71,82
EMD_NCT01016483_1_mek,ZC,ZCSTRESN,Numeric Result/Finding in Standard Units,Num,197,5,35,55,57,60,60,62,64,65,66,71,82
EMD_NCT01016483_1_mek,ZC,ZCSTRESU,Standard Units,Char,197,5,%,%,%,%,%,%,%,%,%,%,%
EMD_NCT01016483_1_mek,ZC,ZCMETHOD,Method of Cardiac Assessment,Char,202,0,ECHOCARDIOGRAPHY,ECHOCARDIOGRAPHY,ECHOCARDIOGRAPHY,ECHOCARDIOGRAPHY,ECHOCARDIOGRAPHY,ECHOCARDIOGRAPHY,ECHOCARDIOGRAPHY,ECHOCARDIOGRAPHY,ECHOCARDIOGRAPHY,MUGA SCAN,MUGA SCAN
EMD_NCT01016483_1_mek,ZC,ZCBLFL,Baseline Flag,Char,43,159,Y,Y,Y,Y,Y,Y,Y,Y,Y,Y,Y
EMD_NCT01016483_1_mek,ZC,VISITNUM,Visit Number,Num,202,0,1,1,1,129,150,150,328,528,1328,16777,20228
EMD_NCT01016483_1_mek,ZC,VISIT,Visit Name,Char,202,0,CYCLE 1 DAY 29,CYCLE 1 DAY 29,CYCLE 1 DAY 50,CYCLE 1 DAY 50,CYCLE 3 DAY 28,CYCLE 5 DAY 28,CYCLE 9 DAY 28,MONOTHERAPY SCREENING,SCREENING,SCREENING,SCREENING
EMD_NCT01016483_1_mek,ZC,VISITDY,Planned Study Day of Visit,Num,178,24,-28,-28,-28,29,29,50,50,112,168,392,2056
EMD_NCT01016483_1_mek,ZC,ETCD,Element Code,Char,198,4,FU,PTP,SCRN,SCRN,TRT_PLA,TRT_PLA,TRT_PLA,TRT_PLA,TRT_PLA,TRT_PLA,TRT_PLA
EMD_NCT01016483_1_mek,ZC,ELEMENT,Description of Element,Char,198,4,Follow-up Period,Gemcitabine and Placebo,Gemcitabine and Placebo,Gemcitabine and Placebo,Gemcitabine and Placebo,Gemcitabine and Placebo,Gemcitabine and Placebo,Pimasertib Monotherapy,Post Treatment Period,Screening,Screening
EMD_NCT01016483_1_mek,ZC,EPOCH,Epoch,Char,198,4,FOLLOW-UP,POST TREATMENT,SCREENING,SCREENING,TREATMENT,TREATMENT,TREATMENT,TREATMENT,TREATMENT,TREATMENT,TREATMENT
EMD_NCT01016483_1_mek,ZC,ZCDTC,Date/Time of Cardiac Assessment,Char,202,0,******,2013-05-06,2013-06-21,2013-07-24,2013-08-20,2013-09-10,2013-10-14,2013-11-19,2014-01-31,2014-05-22,2015-03-16
EMD_NCT01016483_1_mek,ZC,ZCDY,Study Day of Cardiac Assessment,Num,198,4,-21,-7,-1,29,36,52,106,134,199,289,646
EMD_NCT01016483_1_mek,ZO,STUDYID,Study Identifier,Char,6764,0,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003,0200066003
EMD_NCT01016483_1_mek,ZO,DOMAIN,Domain Abbreviation,Char,6764,0,ZO,ZO,ZO,ZO,ZO,ZO,ZO,ZO,ZO,ZO,ZO
EMD_NCT01016483_1_mek,ZO,USUBJID,Unique Subject Identifier,Char,6764,0,1,5,7,11,18,22,27,34,37,41,44
EMD_NCT01016483_1_mek,ZO,ZOSEQ,Sequence Number,Num,6764,0,1,16,31,50,68,89,111,140,180,242,396
EMD_NCT01016483_1_mek,ZO,ZOTESTCD,Ophthalmologic Examination Short Name,Char,6764,0,ANTCHAMB,BLOODVES,CONJUNCT,CORNEA,ERETINOG,INTOCUP,OCT,OPTIC,PERIPH,VISACUIT,VISFIELD
EMD_NCT01016483_1_mek,ZO,ZOTEST,Ophthalmologic Examination Name,Char,6764,0,Anterior Chamber,Blood Vessels,Conjunctiva,Cornea,Electroretinogram,Intraocular Pressure,Optic Disc,Optical Coherence Tomography,Peripheral Retina,Visual Acuity,Visual Field Testing
EMD_NCT01016483_1_mek,ZO,ZOCAT,Category for Ophthalmologic Examination,Char,6764,0,OPHTHALMOLOGIC EXAMINATION,OPHTHALMOLOGIC EXAMINATION,OPHTHALMOLOGIC EXAMINATION,OPHTHALMOLOGIC EXAMINATION,OPHTHALMOLOGIC EXAMINATION,OPHTHALMOLOGIC EXAMINATION,OPHTHALMOLOGIC EXAMINATION,OPHTHALMOLOGIC EXAMINATION,OPHTHALMOLOGIC EXAMINATION,OPHTHALMOLOGIC EXAMINATION,OPHTHALMOLOGIC EXAMINATION
EMD_NCT01016483_1_mek,ZO,ZOSCAT,Subcategory for Ophthalmologic Exam.,Char,6764,0,COLOR VISION TESTING,ELECTRORETINOGRAM,FUNDUS PHOTOGRAPHS,OPHTHALMOSCOPY,OPHTHALMOSCOPY,OPHTHALMOSCOPY,SLIT LAMP EXAMINATION,SLIT LAMP EXAMINATION,SLIT LAMP EXAMINATION,VISUAL ACUITY TESTING,VISUAL FIELD TESTING
EMD_NCT01016483_1_mek,ZO,ZOORRES,Result or Finding in Original Units,Char,5177,1587,0,55,ABNORMAL - CLINICALLY NOT RELEVANT,DONE,NORMAL,NORMAL,NORMAL,NORMAL,NORMAL,NORMAL,NORMAL
EMD_NCT01016483_1_mek,ZO,ZOORRESU,Original Units,Char,380,6384,mmHg,mmHg,mmHg,mmHg,mmHg,mmHg,mmHg,mmHg,mmHg,mmHg,mmHg
EMD_NCT01016483_1_mek,ZO,ZOSTRESC,Character Result/Finding in Std Format,Char,5177,1587,0,55,ABNORMAL - CLINICALLY NOT RELEVANT,DONE,NORMAL,NORMAL,NORMAL,NORMAL,NORMAL,NORMAL,NORMAL
EMD_NCT01016483_1_mek,ZO,ZOSTRESN,Numeric Result/Finding in Standard Units,Num,759,6005,0,11,14,16,17,19,21,54,70,80,99
EMD_NCT01016483_1_mek,ZO,ZOSTRESU,Standard Units,Char,380,6384,mmHg,mmHg,mmHg,mmHg,mmHg,mmHg,mmHg,mmHg,mmHg,mmHg,mmHg
EMD_NCT01016483_1_mek,ZO,ZOSTAT,Completion Status,Char,1571,5193,NOT DONE,NOT DONE,NOT DONE,NOT DONE,NOT DONE,NOT DONE,NOT DONE,NOT DONE,NOT DONE,NOT DONE,NOT DONE
EMD_NCT01016483_1_mek,ZO,ZOREASND,Reason Ophthalmologic Exam. Not Perf.,Char,1571,5193,NOT COLLECTED ON CRF,NOT COLLECTED ON CRF,NOT COLLECTED ON CRF,NOT COLLECTED ON CRF,NOT COLLECTED ON CRF,NOT COLLECTED ON CRF,NOT COLLECTED ON CRF,NOT COLLECTED ON CRF,NOT COLLECTED ON CRF,NOT COLLECTED ON CRF,NOT COLLECTED ON CRF
EMD_NCT01016483_1_mek,ZO,ZOLOC,Location Used for Measurement,Char,6764,0,LEFT EYE,LEFT EYE,LEFT EYE,LEFT EYE,LEFT EYE,LEFT EYE,RIGHT EYE,RIGHT EYE,RIGHT EYE,RIGHT EYE,RIGHT EYE
EMD_NCT01016483_1_mek,ZO,ZOMETHOD,Method of Ophthalmologic Examination,Char,808,5956,FARNSWORTH15 HUE,FARNSWORTH15 HUE,FARNSWORTH15 HUE,FARNSWORTH15 HUE,FARNSWORTH15 HUE,FARNSWORTH15 HUE,GOLDMANN,HUMPHREY,OCTOPUS,OCTOPUS,OTHER
EMD_NCT01016483_1_mek,ZO,ZOBLFL,Baseline Flag,Char,1181,5583,Y,Y,Y,Y,Y,Y,Y,Y,Y,Y,Y
EMD_NCT01016483_1_mek,ZO,VISITNUM,Visit Number,Num,6764,0,1,1,1,129,150,150,328,722,1928,20001,26877
EMD_NCT01016483_1_mek,ZO,VISIT,Visit Name,Char,6764,0,CYCLE 1 DAY 2 UNSCHEDULED 1,CYCLE 1 DAY 29,CYCLE 1 DAY 50,CYCLE 1 DAY 50,CYCLE 3 DAY 28,CYCLE 5 DAY 28,CYCLE 9 DAY 28,MONOTHERAPY SCREENING,SCREENING,SCREENING,TREATMENT TERMINATION UNSCHEDULED 2
EMD_NCT01016483_1_mek,ZO,VISITDY,Planned Study Day of Visit,Num,5627,1137,-28,-28,-28,29,29,50,50,112,168,392,2056
EMD_NCT01016483_1_mek,ZO,ETCD,Element Code,Char,5952,812,MONOTHER,MSCRN,SCRN,SCRN,TRT_PLA,TRT_PLA,TRT_PLA,TRT_PLA,TRT_PLA,TRT_PLA,TRT_PLA
EMD_NCT01016483_1_mek,ZO,ELEMENT,Description of Element,Char,5952,812,Gemcitabine and Placebo,Gemcitabine and Placebo,Gemcitabine and Placebo,Gemcitabine and Placebo,Gemcitabine and Placebo,Gemcitabine and Placebo,Gemcitabine and Placebo,Pimasertib Monotherapy,Screening,Screening,Screening
EMD_NCT01016483_1_mek,ZO,EPOCH,Epoch,Char,5952,812,MONOTHERAPY POST TREATMENT,MONOTHERAPY TREATMENT,SCREENING,SCREENING,TREATMENT,TREATMENT,TREATMENT,TREATMENT,TREATMENT,TREATMENT,TREATMENT
EMD_NCT01016483_1_mek,ZO,ZODTC,Date/Time of Ophthalmologic Examination,Char,6764,0,******,******,2013-05-15,2013-07-02,2013-07-31,2013-08-27,2013-09-24,2013-11-07,2013-12-26,2014-03-27,2015-03-16
EMD_NCT01016483_1_mek,ZO,ZODY,Study Day of Ophthalmologic Examination,Num,5956,808,-506,-6,-1,29,35,55,98,119,177,276,646